Drugs interactions for Invokamet ®
- 68 Major drug interactions (including ingredients like Abametapir, Abemaciclib, Abemaciclib)
- 706 Moderate drug interactions (including ingredients like Abrocitinib, Acarbose, Acebutolol)
- 911 Minor drug interactions (including ingredients like Abacavir, Abacavir, Abaloparatide)
1685 interactions for Invokamet ®The serum concentration of Canagliflozin can be increased when it is combined with Abametapir.The excretion of Abemaciclib can be decreased when combined with Metformin.The serum concentration of Abemaciclib can be increased when it is combined with Canagliflozin.The metabolism of Canagliflozin can be decreased when combined with Amiodarone.The metabolism of Canagliflozin can be decreased when combined with Atazanavir.The serum concentration of Axitinib can be increased when it is combined with Canagliflozin.The serum concentration of Bendamustine can be increased when it is combined with Canagliflozin.The serum concentration of Binimetinib can be increased when it is combined with Canagliflozin.The serum concentration of Bortezomib can be increased when it is combined with Canagliflozin.The serum concentration of Cabergoline can be increased when it is combined with Canagliflozin.The serum concentration of Carfilzomib can be increased when it is combined with Canagliflozin.The serum concentration of Ceritinib can be increased when it is combined with Canagliflozin.The metabolism of Canagliflozin can be decreased when combined with Clarithromycin.The serum concentration of Cobimetinib can be increased when it is combined with Canagliflozin.The metabolism of Canagliflozin can be decreased when combined with Conivaptan.The serum concentration of Crizotinib can be increased when it is combined with Canagliflozin.The metabolism of Canagliflozin can be decreased when combined with Curcumin.The serum concentration of Cyclosporine can be increased when it is combined with Canagliflozin.The serum concentration of Dacomitinib can be increased when it is combined with Canagliflozin.The serum concentration of Dactinomycin can be increased when it is combined with Canagliflozin.The metabolism of Canagliflozin can be decreased when combined with Danazol.The metabolism of Canagliflozin can be decreased when combined with Darunavir.The serum concentration of Dasatinib can be increased when it is combined with Canagliflozin.The metabolism of Canagliflozin can be decreased when combined with Elvitegravir.The metabolism of Canagliflozin can be decreased when combined with Ergotamine.The serum concentration of Etoposide can be increased when it is combined with Canagliflozin.The serum concentration of Gemcitabine can be increased when it is combined with Canagliflozin.The serum concentration of Imipramine can be increased when it is combined with Canagliflozin.The metabolism of Canagliflozin can be decreased when combined with Indinavir.The risk or severity of lactic acidosis can be increased when Iomeprol is combined with Metformin.The metabolism of Canagliflozin can be decreased when combined with Itraconazole.The metabolism of Canagliflozin can be decreased when combined with Ketoconazole.The metabolism of Canagliflozin can be decreased when combined with Levoketoconazole.The metabolism of Canagliflozin can be decreased when combined with Lonafarnib.The metabolism of Canagliflozin can be decreased when combined with Lopinavir.The metabolism of Canagliflozin can be decreased when combined with Methimazole.The metabolism of Canagliflozin can be decreased when combined with Midostaurin.The metabolism of Canagliflozin can be increased when combined with Mitotane.The metabolism of Canagliflozin can be decreased when combined with Nefazodone.The metabolism of Canagliflozin can be decreased when combined with Nelfinavir.The metabolism of Canagliflozin can be decreased when combined with Nilotinib.The serum concentration of Nortriptyline can be increased when it is combined with Canagliflozin.The serum concentration of Osimertinib can be increased when it is combined with Canagliflozin.The serum concentration of Panobinostat can be increased when it is combined with Canagliflozin.The serum concentration of Pomalidomide can be increased when it is combined with Canagliflozin.The metabolism of Canagliflozin can be decreased when combined with Posaconazole.The excretion of Procainamide can be decreased when combined with Metformin.The serum concentration of Quinidine can be increased when it is combined with Canagliflozin.The serum concentration of Regorafenib can be increased when it is combined with Canagliflozin.The metabolism of Canagliflozin can be decreased when combined with Ribociclib.The metabolism of Canagliflozin can be increased when combined with Rifapentine.The serum concentration of Rimegepant can be increased when it is combined with Canagliflozin.The serum concentration of Romidepsin can be increased when it is combined with Canagliflozin.The metabolism of Canagliflozin can be decreased when combined with Saquinavir.The excretion of Silodosin can be decreased when combined with Canagliflozin.The serum concentration of Sirolimus can be increased when it is combined with Canagliflozin.The risk or severity of hyperkalemia can be increased when Canagliflozin is combined with Spironolactone.The metabolism of Canagliflozin can be decreased when combined with Telithromycin.The serum concentration of Temsirolimus can be increased when it is combined with Canagliflozin.The serum concentration of Tepotinib can be increased when it is combined with Canagliflozin.The metabolism of Canagliflozin can be decreased when combined with Tipranavir.The serum concentration of Tolvaptan can be increased when it is combined with Canagliflozin.The excretion of Topotecan can be decreased when combined with Metformin.The serum concentration of Trastuzumab emtansine can be increased when it is combined with Canagliflozin.The serum concentration of Trimipramine can be increased when it is combined with Canagliflozin.The serum concentration of Venetoclax can be increased when it is combined with Canagliflozin.The serum concentration of Vinblastine can be increased when it is combined with Canagliflozin.The metabolism of Canagliflozin can be decreased when combined with Voriconazole.The serum concentration of Canagliflozin can be increased when it is combined with Abrocitinib.Canagliflozin may increase the hypoglycemic activities of Acarbose.The therapeutic efficacy of Metformin can be increased when used in combination with Acebutolol.The therapeutic efficacy of Canagliflozin can be increased when used in combination with Acebutolol.The risk or severity of lactic acidosis can be increased when Acetazolamide is combined with Metformin.The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Metformin.The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Canagliflozin.The excretion of Acyclovir can be decreased when combined with Metformin.The serum concentration of Canagliflozin can be increased when it is combined with Adagrasib.The serum concentration of Afatinib can be increased when it is combined with Canagliflozin.The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Metformin.The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Canagliflozin.Canagliflozin may increase the hypoglycemic activities of Alogliptin.The serum concentration of Amantadine can be increased when it is combined with Metformin.The serum concentration of Ambrisentan can be increased when it is combined with Canagliflozin.The risk or severity of hyperglycemia can be increased when Amcinonide is combined with Metformin.The risk or severity of hyperglycemia can be increased when Amcinonide is combined with Canagliflozin.Metformin may decrease the excretion rate of Amikacin which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Amikacin which could result in a higher serum level.The serum concentration of Metformin can be increased when it is combined with Amiloride.Aminosalicylic acid may increase the hypoglycemic activities of Metformin.Aminosalicylic acid may increase the hypoglycemic activities of Canagliflozin.The serum concentration of Metformin can be increased when it is combined with Amiodarone.Amitriptyline may decrease the hypoglycemic activities of Metformin.Amitriptyline may decrease the hypoglycemic activities of Canagliflozin.The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Metformin.The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Canagliflozin.The serum concentration of Canagliflozin can be decreased when it is combined with Amobarbital.Amoxapine may decrease the hypoglycemic activities of Metformin.Amoxapine may decrease the hypoglycemic activities of Canagliflozin.The serum concentration of Metformin can be increased when it is combined with Apalutamide.The serum concentration of Canagliflozin can be decreased when it is combined with Apalutamide.The serum concentration of Apixaban can be increased when it is combined with Canagliflozin.The metabolism of Canagliflozin can be decreased when combined with Aprepitant.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Aripiprazole.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Arsenic trioxide.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Articaine.The serum concentration of Canagliflozin can be increased when it is combined with Asciminib.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Asenapine.The serum concentration of Canagliflozin can be increased when it is combined with Asunaprevir.The serum concentration of Metformin can be increased when it is combined with Atenolol.The therapeutic efficacy of Canagliflozin can be increased when used in combination with Atenolol.The serum concentration of Avanafil can be increased when it is combined with Canagliflozin.The risk or severity of hypotension, hyperkalemia, and reduced intravascular volume can be increased when Canagliflozin is combined with Azilsartan medoxomil.The therapeutic efficacy of Metformin can be decreased when used in combination with Baclofen.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Baclofen.Balsalazide may increase the hypoglycemic activities of Metformin.Balsalazide may increase the hypoglycemic activities of Canagliflozin.The excretion of Baricitinib can be decreased when combined with Metformin.The risk or severity of hyperglycemia can be increased when Beclomethasone dipropionate is combined with Canagliflozin.The serum concentration of Belinostat can be increased when it is combined with Canagliflozin.The serum concentration of Canagliflozin can be increased when it is combined with Belumosudil.The risk or severity of hypoglycemia can be increased when Benazepril is combined with Metformin.The risk or severity of hypoglycemia can be increased when Benazepril is combined with Canagliflozin.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Bendroflumethiazide.The serum concentration of Berotralstat can be increased when it is combined with Canagliflozin.The risk or severity of hyperglycemia can be increased when Betamethasone is combined with Canagliflozin.The therapeutic efficacy of Metformin can be increased when used in combination with Betaxolol.The therapeutic efficacy of Canagliflozin can be increased when used in combination with Betaxolol.The serum concentration of Betrixaban can be increased when it is combined with Canagliflozin.Bexagliflozin may increase the hypoglycemic activities of Metformin.Canagliflozin may increase the hypoglycemic activities of Bexagliflozin.Bismuth subsalicylate may increase the hypoglycemic activities of Metformin.Bismuth subsalicylate may increase the hypoglycemic activities of Canagliflozin.The therapeutic efficacy of Metformin can be increased when used in combination with Bisoprolol.The therapeutic efficacy of Canagliflozin can be increased when used in combination with Bisoprolol.The serum concentration of Bosutinib can be increased when it is combined with Canagliflozin.The serum concentration of Brentuximab vedotin can be increased when it is combined with Canagliflozin.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Brexpiprazole.The excretion of Metformin can be decreased when combined with Brigatinib.The risk or severity of hypoglycemia can be increased when Metformin is combined with Bromocriptine.Canagliflozin may increase the hypoglycemic activities of Bromocriptine.The risk or severity of hyperglycemia can be increased when Budesonide is combined with Metformin.The risk or severity of hyperglycemia can be increased when Budesonide is combined with Canagliflozin.The risk or severity of hypotension can be increased when Canagliflozin is combined with Bumetanide.The excretion of Metformin can be decreased when combined with Bupropion.The serum concentration of Canagliflozin can be decreased when it is combined with Butalbital.The risk or severity of hypotension, hyperkalemia, and reduced intravascular volume can be increased when Canagliflozin is combined with Candesartan cilexetil.The metabolism of Canagliflozin can be decreased when combined with Cannabidiol.The serum concentration of Metformin can be increased when it is combined with Capivasertib.The excretion of Metformin can be decreased when combined with Capmatinib.The serum concentration of Canagliflozin can be increased when it is combined with Capmatinib.Metformin may decrease the excretion rate of Capreomycin which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Capreomycin which could result in a higher serum level.The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Canagliflozin is combined with Captopril.Metformin may decrease the excretion rate of Carbamazepine which could result in a higher serum level.The metabolism of Canagliflozin can be increased when combined with Carbamazepine.The therapeutic efficacy of Metformin can be increased when used in combination with Carvedilol.The therapeutic efficacy of Canagliflozin can be increased when used in combination with Carvedilol.The serum concentration of Canagliflozin can be decreased when it is combined with Cenobamate.Cephalexin may decrease the excretion rate of Metformin which could result in a higher serum level.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Chlorothiazide.The serum concentration of Metformin can be increased when it is combined with Chlorpheniramine.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Chlorpromazine.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Chlorthalidone.The serum concentration of Metformin can be increased when it is combined with Choline.Choline salicylate may increase the hypoglycemic activities of Metformin.Choline salicylate may increase the hypoglycemic activities of Canagliflozin.The risk or severity of hyperglycemia can be increased when Ciclesonide is combined with Canagliflozin.The therapeutic efficacy of Metformin can be increased when used in combination with Ciprofloxacin.The therapeutic efficacy of Canagliflozin can be increased when used in combination with Ciprofloxacin.Canagliflozin may decrease the excretion rate of Cisplatin which could result in a higher serum level.The risk or severity of hypoglycemia can be increased when Citalopram is combined with Metformin.The risk or severity of hypoglycemia can be increased when Citalopram is combined with Canagliflozin.The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Metformin.The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Canagliflozin.The serum concentration of Clobazam can be increased when it is combined with Canagliflozin.The risk or severity of hyperglycemia can be increased when Clobetasol propionate is combined with Canagliflozin.The risk or severity of hyperglycemia can be increased when Clocortolone is combined with Metformin.The risk or severity of hyperglycemia can be increased when Clocortolone is combined with Canagliflozin.The serum concentration of Clomifene can be increased when it is combined with Canagliflozin.Clomipramine may decrease the hypoglycemic activities of Metformin.Clomipramine may decrease the hypoglycemic activities of Canagliflozin.The serum concentration of Metformin can be increased when it is combined with Clopidogrel.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Clozapine.The serum concentration of Canagliflozin can be increased when it is combined with Cobicistat.The serum concentration of Colchicine can be increased when it is combined with Canagliflozin.Metformin may decrease the excretion rate of Colistin which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Colistin which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Conjugated estrogens.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Conjugated estrogens.The risk or severity of hyperglycemia can be increased when Corticotropin is combined with Canagliflozin.The risk or severity of hyperglycemia can be increased when Cortisone acetate is combined with Canagliflozin.The serum concentration of Metformin can be increased when it is combined with Crizotinib.The serum concentration of Dabigatran etexilate can be increased when it is combined with Canagliflozin.The serum concentration of Canagliflozin can be decreased when it is combined with Dabrafenib.The serum concentration of Canagliflozin can be increased when it is combined with Danicopan.Dapagliflozin may increase the hypoglycemic activities of Canagliflozin.The serum concentration of Daptomycin can be increased when it is combined with Canagliflozin.The serum concentration of Darolutamide can be increased when it is combined with Canagliflozin.The serum concentration of Dasabuvir can be increased when it is combined with Canagliflozin.The metabolism of Canagliflozin can be decreased when combined with Deferasirox.The risk or severity of hyperglycemia can be increased when Deflazacort is combined with Canagliflozin.The therapeutic efficacy of Metformin can be increased when used in combination with Delafloxacin.The therapeutic efficacy of Canagliflozin can be increased when used in combination with Delafloxacin.Desipramine may decrease the hypoglycemic activities of Metformin.Desipramine may decrease the hypoglycemic activities of Canagliflozin.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Desogestrel.The risk or severity of hyperglycemia can be increased when Desonide is combined with Metformin.The risk or severity of hyperglycemia can be increased when Desonide is combined with Canagliflozin.The risk or severity of hyperglycemia can be increased when Desoximetasone is combined with Metformin.The risk or severity of hyperglycemia can be increased when Desoximetasone is combined with Canagliflozin.The risk or severity of hypoglycemia can be increased when Desvenlafaxine is combined with Metformin.The risk or severity of hypoglycemia can be increased when Desvenlafaxine is combined with Canagliflozin.The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Canagliflozin.The risk or severity of hyperglycemia can be increased when Dexamethasone acetate is combined with Metformin.The risk or severity of hyperglycemia can be increased when Dexamethasone acetate is combined with Canagliflozin.The serum concentration of Metformin can be increased when it is combined with Dexchlorpheniramine maleate.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Diazoxide.The risk or severity of lactic acidosis can be increased when Diclofenamide is combined with Metformin.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Dienogest.The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Metformin.The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Canagliflozin.Diflunisal may increase the hypoglycemic activities of Metformin.Diflunisal may increase the hypoglycemic activities of Canagliflozin.The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Metformin.The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Canagliflozin.The serum concentration of Digoxin can be increased when it is combined with Metformin.The serum concentration of Digoxin can be increased when it is combined with Canagliflozin.The risk or severity of hypoglycemia can be increased when Diltiazem is combined with Metformin.The metabolism of Canagliflozin can be decreased when combined with Diltiazem.The serum concentration of Metformin can be increased when it is combined with Dinoprostone.The serum concentration of Canagliflozin can be increased when it is combined with Diosmin.The serum concentration of Metformin can be increased when it is combined with Diphenhydramine.Dipotassium phosphate may increase the hyperkalemic activities of Canagliflozin.The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Metformin.Canagliflozin may increase the hypoglycemic activities of Disopyramide.The serum concentration of Dofetilide can be increased when it is combined with Metformin.The serum concentration of Metformin can be increased when it is combined with Dolutegravir.The serum concentration of Dolutegravir can be increased when it is combined with Canagliflozin.The serum concentration of Dopamine can be increased when it is combined with Metformin.Doxepin may decrease the hypoglycemic activities of Metformin.Doxepin may decrease the hypoglycemic activities of Canagliflozin.The serum concentration of Doxorubicin can be increased when it is combined with Canagliflozin.The serum concentration of Metformin can be increased when it is combined with Dronedarone.The metabolism of Canagliflozin can be decreased when combined with Dronedarone.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Drospirenone.The risk or severity of hypoglycemia can be increased when Metformin is combined with Dulaglutide.Canagliflozin may increase the hypoglycemic activities of Dulaglutide.The risk or severity of hypoglycemia can be increased when Duloxetine is combined with Metformin.The serum concentration of Duvelisib can be increased when it is combined with Canagliflozin.The serum concentration of Edoxaban can be increased when it is combined with Canagliflozin.The serum concentration of Canagliflozin can be decreased when it is combined with Efavirenz.The serum concentration of Canagliflozin can be increased when it is combined with Elacestrant.The serum concentration of Elagolix can be increased when it is combined with Canagliflozin.The serum concentration of Elbasvir can be increased when it is combined with Canagliflozin.The serum concentration of Canagliflozin can be increased when it is combined with Eliglustat.The metabolism of Canagliflozin can be decreased when combined with Eltrombopag.Canagliflozin may increase the hypoglycemic activities of Empagliflozin.The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Canagliflozin is combined with Enalapril.The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Canagliflozin is combined with Enalaprilat.The serum concentration of Metformin can be increased when it is combined with Enasidenib.The serum concentration of Canagliflozin can be increased when it is combined with Enasidenib.The serum concentration of Metformin can be increased when it is combined with Encorafenib.The serum concentration of Encorafenib can be increased when it is combined with Canagliflozin.The serum concentration of Enfortumab vedotin can be increased when it is combined with Canagliflozin.The serum concentration of Canagliflozin can be increased when it is combined with Entrectinib.The serum concentration of Canagliflozin can be decreased when it is combined with Enzalutamide.The serum concentration of Canagliflozin can be increased when it is combined with Epcoritamab.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Epinephrine.The risk or severity of hypotension, hyperkalemia, and reduced intravascular volume can be increased when Canagliflozin is combined with Eprosartan.The serum concentration of Metformin can be increased when it is combined with Erdafitinib.The serum concentration of Canagliflozin can be increased when it is combined with Erdafitinib.Canagliflozin may increase the hypoglycemic activities of Ertugliflozin.The serum concentration of Canagliflozin can be increased when it is combined with Erythromycin.The risk or severity of hypoglycemia can be increased when Escitalopram is combined with Metformin.The risk or severity of hypoglycemia can be increased when Escitalopram is combined with Canagliflozin.The therapeutic efficacy of Metformin can be decreased when used in combination with Estetrol.The risk or severity of hyperkalemia can be increased when Canagliflozin is combined with Estetrol.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Estradiol.The serum concentration of Metformin can be increased when it is combined with Estradiol acetate.The serum concentration of Metformin can be increased when it is combined with Estradiol cypionate.The serum concentration of Metformin can be increased when it is combined with Estradiol valerate.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Estrone sulfate.The risk or severity of hypotension can be increased when Canagliflozin is combined with Etacrynic acid.Ethanol may increase the hypotensive activities of Canagliflozin.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Ethinylestradiol.The risk or severity of hypoglycemia can be increased when Ethosuximide is combined with Metformin.The risk or severity of hypoglycemia can be increased when Ethosuximide is combined with Canagliflozin.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Ethynodiol diacetate.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Etonogestrel.The serum concentration of Everolimus can be increased when it is combined with Canagliflozin.The risk or severity of hypoglycemia can be increased when Exenatide is combined with Metformin.Canagliflozin may increase the hypoglycemic activities of Exenatide.The serum concentration of Metformin can be increased when it is combined with Famotidine.Fedratinib may decrease the excretion rate of Metformin which could result in a higher serum level.The serum concentration of Canagliflozin can be increased when it is combined with Fedratinib.The risk or severity of hypoglycemia can be increased when Felodipine is combined with Metformin.The risk or severity of hypoglycemia can be increased when Felodipine is combined with Canagliflozin.The serum concentration of Metformin can be increased when it is combined with Fexinidazole.The serum concentration of Fexofenadine can be increased when it is combined with Canagliflozin.The serum concentration of Canagliflozin can be increased when it is combined with Flibanserin.The risk or severity of hypoglycemia can be increased when Metformin is combined with Fluconazole.The risk or severity of hypoglycemia can be increased when Canagliflozin is combined with Fluconazole.The risk or severity of hyperglycemia can be increased when Fludrocortisone is combined with Canagliflozin.The risk or severity of hyperglycemia can be increased when Flunisolide is combined with Metformin.The risk or severity of hyperglycemia can be increased when Flunisolide is combined with Canagliflozin.The risk or severity of hyperglycemia can be increased when Fluocinolone acetonide is combined with Metformin.The risk or severity of hyperglycemia can be increased when Fluocinolone acetonide is combined with Canagliflozin.The risk or severity of hyperglycemia can be increased when Fluocinonide is combined with Metformin.The risk or severity of hyperglycemia can be increased when Fluocinonide is combined with Canagliflozin.The risk or severity of hyperglycemia can be increased when Fluorometholone is combined with Canagliflozin.The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Metformin.The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Canagliflozin.The risk or severity of hyperglycemia can be increased when Flurandrenolide is combined with Metformin.The risk or severity of hyperglycemia can be increased when Flurandrenolide is combined with Canagliflozin.The serum concentration of Metformin can be increased when it is combined with Flurazepam.The risk or severity of hyperglycemia can be increased when Fluticasone furoate is combined with Canagliflozin.The risk or severity of hyperglycemia can be increased when Fluticasone propionate is combined with Metformin.The risk or severity of hyperglycemia can be increased when Fluticasone propionate is combined with Canagliflozin.The risk or severity of hypoglycemia can be increased when Fluvoxamine is combined with Metformin.The risk or severity of hypoglycemia can be increased when Fluvoxamine is combined with Canagliflozin.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Fosamprenavir.The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Canagliflozin is combined with Fosinopril.The metabolism of Canagliflozin can be decreased when combined with Fosnetupitant.The serum concentration of Canagliflozin can be decreased when it is combined with Fosphenytoin.The serum concentration of Fostemsavir can be increased when it is combined with Canagliflozin.The risk or severity of hypotension can be increased when Canagliflozin is combined with Furosemide.The metabolism of Canagliflozin can be decreased when combined with Fusidic acid.The serum concentration of Futibatinib can be increased when it is combined with Canagliflozin.The excretion of Ganciclovir can be decreased when combined with Metformin.The therapeutic efficacy of Metformin can be increased when used in combination with Gatifloxacin.The therapeutic efficacy of Canagliflozin can be increased when used in combination with Gatifloxacin.The therapeutic efficacy of Metformin can be increased when used in combination with Gemifloxacin.The therapeutic efficacy of Canagliflozin can be increased when used in combination with Gemifloxacin.Metformin may decrease the excretion rate of Gentamicin which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Gentamicin which could result in a higher serum level.The serum concentration of Gilteritinib can be increased when it is combined with Canagliflozin.The excretion of Metformin can be decreased when combined with Glasdegib.The serum concentration of Glasdegib can be increased when it is combined with Canagliflozin.The serum concentration of Glecaprevir can be increased when it is combined with Canagliflozin.Canagliflozin may increase the hypoglycemic activities of Glimepiride.Canagliflozin may increase the hypoglycemic activities of Glipizide.The serum concentration of Canagliflozin can be increased when it is combined with Glofitamab.Canagliflozin may increase the hypoglycemic activities of Glyburide.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Goserelin.The serum concentration of Grazoprevir can be increased when it is combined with Canagliflozin.The serum concentration of Metformin can be increased when it is combined with Guanidine.The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Metformin.The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Canagliflozin.The serum concentration of Haloperidol can be increased when it is combined with Canagliflozin.The serum concentration of Histamine can be increased when it is combined with Metformin.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Histrelin.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Hydrochlorothiazide.The risk or severity of hyperglycemia can be increased when Hydrocortisone is combined with Canagliflozin.The risk or severity of hyperglycemia can be increased when Hydrocortisone acetate is combined with Metformin.The risk or severity of hyperglycemia can be increased when Hydrocortisone acetate is combined with Canagliflozin.The risk or severity of hyperglycemia can be increased when Hydrocortisone butyrate is combined with Metformin.The risk or severity of hyperglycemia can be increased when Hydrocortisone butyrate is combined with Canagliflozin.The risk or severity of hyperglycemia can be increased when Hydrocortisone probutate is combined with Metformin.The risk or severity of hyperglycemia can be increased when Hydrocortisone probutate is combined with Canagliflozin.The risk or severity of hyperglycemia can be increased when Hydrocortisone succinate is combined with Metformin.The risk or severity of hyperglycemia can be increased when Hydrocortisone succinate is combined with Canagliflozin.The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Metformin.The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Canagliflozin.The therapeutic efficacy of Metformin can be decreased when used in combination with Hydroflumethiazide.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Hydroflumethiazide.The therapeutic efficacy of Metformin can be increased when used in combination with Hydroxychloroquine.The therapeutic efficacy of Canagliflozin can be increased when used in combination with Hydroxychloroquine.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Hydroxyprogesterone caproate.The serum concentration of Idelalisib can be increased when it is combined with Canagliflozin.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Iloperidone.The serum concentration of Metformin can be increased when it is combined with Imatinib.Imipramine may decrease the hypoglycemic activities of Metformin.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Indapamide.The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Metformin.The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Canagliflozin.The risk or severity of adverse effects can be increased when Insulin aspart is combined with Metformin.The risk or severity of hypoglycemia can be increased when Insulin aspart is combined with Canagliflozin.The risk or severity of adverse effects can be increased when Insulin degludec is combined with Metformin.The risk or severity of hypoglycemia can be increased when Insulin degludec is combined with Canagliflozin.The risk or severity of adverse effects can be increased when Insulin detemir is combined with Metformin.The risk or severity of hypoglycemia can be increased when Insulin detemir is combined with Canagliflozin.The risk or severity of adverse effects can be increased when Insulin glargine is combined with Metformin.The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Canagliflozin.The risk or severity of adverse effects can be increased when Insulin glulisine is combined with Metformin.The risk or severity of hypoglycemia can be increased when Insulin glulisine is combined with Canagliflozin.The risk or severity of adverse effects can be increased when Insulin human is combined with Metformin.The risk or severity of hypoglycemia can be increased when Insulin human is combined with Canagliflozin.The risk or severity of adverse effects can be increased when Insulin lispro is combined with Metformin.The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Canagliflozin.The risk or severity of adverse effects can be increased when Iodixanol is combined with Metformin.The risk or severity of adverse effects can be increased when Iohexol is combined with Metformin.The risk or severity of adverse effects can be increased when Iopamidol is combined with Metformin.The risk or severity of lactic acidosis can be increased when Iopromide is combined with Metformin.The risk or severity of adverse effects can be increased when Ioversol is combined with Metformin.The risk or severity of hypotension, hyperkalemia, and reduced intravascular volume can be increased when Canagliflozin is combined with Irbesartan.The serum concentration of Metformin can be increased when it is combined with Isavuconazonium.The serum concentration of Canagliflozin can be increased when it is combined with Isavuconazonium.Isocarboxazid may increase the orthostatic hypotensive activities of Canagliflozin.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Isoniazid.The risk or severity of hypoglycemia can be increased when Isradipine is combined with Metformin.The metabolism of Canagliflozin can be decreased when combined with Isradipine.The excretion of Metformin can be decreased when combined with Istradefylline.The serum concentration of Canagliflozin can be increased when it is combined with Istradefylline.The serum concentration of Canagliflozin can be increased when it is combined with Ivacaftor.The metabolism of Canagliflozin can be increased when combined with Ivosidenib.The serum concentration of Canagliflozin can be increased when it is combined with Ixabepilone.The therapeutic efficacy of Metformin can be increased when used in combination with Labetalol.The therapeutic efficacy of Canagliflozin can be increased when used in combination with Labetalol.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Lanreotide.The serum concentration of Canagliflozin can be increased when it is combined with Lapatinib.The serum concentration of Canagliflozin can be increased when it is combined with Lasmiditan.The serum concentration of Ledipasvir can be increased when it is combined with Canagliflozin.Canagliflozin may decrease the excretion rate of Lefamulin which could result in a higher serum level.The serum concentration of Lemborexant can be increased when it is combined with Canagliflozin.The serum concentration of Lenacapavir can be increased when it is combined with Canagliflozin.The serum concentration of Metformin can be increased when it is combined with Lenvatinib.The serum concentration of Lenvatinib can be increased when it is combined with Canagliflozin.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Leuprolide.The risk or severity of hypoglycemia can be increased when Levamlodipine is combined with Metformin.The risk or severity of hypoglycemia can be increased when Levamlodipine is combined with Canagliflozin.The therapeutic efficacy of Metformin can be increased when used in combination with Levofloxacin.The therapeutic efficacy of Canagliflozin can be increased when used in combination with Levofloxacin.The serum concentration of Metformin can be increased when it is combined with Levoketoconazole.The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Metformin.The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Canagliflozin.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Levonorgestrel.The therapeutic efficacy of Metformin can be decreased when used in combination with Levothyroxine.Canagliflozin may increase the hypoglycemic activities of Linagliptin.Linezolid may increase the orthostatic hypotensive activities of Canagliflozin.The therapeutic efficacy of Metformin can be decreased when used in combination with Liothyronine.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Liothyronine.The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Canagliflozin.The risk or severity of hypoglycemia can be increased when Liraglutide is combined with Metformin.Canagliflozin may increase the hypoglycemic activities of Liraglutide.The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Canagliflozin is combined with Lisinopril.The risk or severity of hypoglycemia can be increased when Metformin is combined with Lixisenatide.Canagliflozin may increase the hypoglycemic activities of Lixisenatide.The therapeutic efficacy of Metformin can be increased when used in combination with Lomefloxacin.The therapeutic efficacy of Canagliflozin can be increased when used in combination with Lomefloxacin.The serum concentration of Canagliflozin can be increased when it is combined with Lomitapide.The therapeutic efficacy of Metformin can be decreased when used in combination with Lonapegsomatropin.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Lonapegsomatropin.The serum concentration of Loncastuximab tesirine can be increased when it is combined with Canagliflozin.The risk or severity of hypotension, hyperkalemia, and reduced intravascular volume can be increased when Canagliflozin is combined with Losartan.The serum concentration of Canagliflozin can be increased when it is combined with Loxapine.The serum concentration of Canagliflozin can be decreased when it is combined with Lumacaftor.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Lurasidone.The serum concentration of Lusutrombopag can be increased when it is combined with Canagliflozin.The risk or severity of hypoglycemia can be increased when Magnesium sulfate is combined with Metformin.The risk or severity of hypoglycemia can be increased when Magnesium sulfate is combined with Canagliflozin.The serum concentration of Mannitol can be increased when it is combined with Canagliflozin.The serum concentration of Canagliflozin can be increased when it is combined with Maribavir.The serum concentration of Canagliflozin can be decreased when it is combined with Mavacamten.The excretion of Mavorixafor can be decreased when combined with Canagliflozin.The risk or severity of hypoglycemia can be increased when Mecasermin is combined with Metformin.Canagliflozin may increase the hypoglycemic activities of Mecasermin.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Medroxyprogesterone acetate.The risk or severity of hyperglycemia can be increased when Medrysone is combined with Metformin.The risk or severity of hyperglycemia can be increased when Medrysone is combined with Canagliflozin.The metabolism of Canagliflozin can be decreased when combined with Mefenamic acid.The serum concentration of Canagliflozin can be increased when it is combined with Mefloquine.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Megestrol acetate.Mesalazine may increase the hypoglycemic activities of Metformin.Mesalazine may increase the hypoglycemic activities of Canagliflozin.The risk or severity of lactic acidosis can be increased when Methazolamide is combined with Metformin.The serum concentration of Canagliflozin can be decreased when it is combined with Methohexital.The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Metformin.The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Canagliflozin.Methyl salicylate may increase the hypoglycemic activities of Metformin.Methyl salicylate may increase the hypoglycemic activities of Canagliflozin.The serum concentration of Metformin can be increased when it is combined with Methylene blue.Methylene blue may increase the orthostatic hypotensive activities of Canagliflozin.The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Canagliflozin.The risk or severity of hyperglycemia can be increased when Methylprednisolone hemisuccinate is combined with Metformin.The risk or severity of hyperglycemia can be increased when Methylprednisolone hemisuccinate is combined with Canagliflozin.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Metolazone.The therapeutic efficacy of Metformin can be increased when used in combination with Metoprolol.The therapeutic efficacy of Canagliflozin can be increased when used in combination with Metoprolol.The metabolism of Canagliflozin can be decreased when combined with Miconazole.The serum concentration of Midazolam can be increased when it is combined with Canagliflozin.The risk or severity of hypoglycemia can be increased when Mifepristone is combined with Metformin.Canagliflozin may increase the hypoglycemic activities of Mifepristone.Canagliflozin may increase the hypoglycemic activities of Miglitol.The risk or severity of hypoglycemia can be increased when Milnacipran is combined with Metformin.The risk or severity of hypoglycemia can be increased when Milnacipran is combined with Canagliflozin.The serum concentration of Canagliflozin can be increased when it is combined with Mirabegron.The serum concentration of Canagliflozin can be increased when it is combined with Mitapivat.The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Canagliflozin is combined with Moexipril.The risk or severity of hyperglycemia can be increased when Mometasone furoate is combined with Canagliflozin.Monopotassium phosphate may increase the hyperkalemic activities of Canagliflozin.The serum concentration of Morphine can be increased when it is combined with Canagliflozin.The therapeutic efficacy of Metformin can be increased when used in combination with Moxifloxacin.The therapeutic efficacy of Canagliflozin can be increased when used in combination with Moxifloxacin.The therapeutic efficacy of Metformin can be increased when used in combination with Nadolol.The therapeutic efficacy of Canagliflozin can be increased when used in combination with Nadolol.The serum concentration of Naloxegol can be increased when it is combined with Canagliflozin.Canagliflozin may increase the hypoglycemic activities of Nateglinide.The therapeutic efficacy of Metformin can be increased when used in combination with Nebivolol.The therapeutic efficacy of Canagliflozin can be increased when used in combination with Nebivolol.The risk or severity of hypoglycemia can be increased when Nefazodone is combined with Metformin.Metformin may decrease the excretion rate of Neomycin which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Neomycin which could result in a higher serum level.The serum concentration of Canagliflozin can be increased when it is combined with Neratinib.The metabolism of Canagliflozin can be decreased when combined with Netupitant.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Niacin.The risk or severity of hypoglycemia can be increased when Nicardipine is combined with Metformin.The metabolism of Canagliflozin can be decreased when combined with Nicardipine.The serum concentration of Metformin can be increased when it is combined with Nicotine.The risk or severity of hypoglycemia can be increased when Nifedipine is combined with Metformin.The risk or severity of hypoglycemia can be increased when Nifedipine is combined with Canagliflozin.The risk or severity of hypoglycemia can be increased when Nimodipine is combined with Metformin.The risk or severity of hypoglycemia can be increased when Nimodipine is combined with Canagliflozin.The serum concentration of Nintedanib can be increased when it is combined with Canagliflozin.The serum concentration of Nirogacestat can be increased when it is combined with Canagliflozin.The risk or severity of hypoglycemia can be increased when Nisoldipine is combined with Metformin.The risk or severity of hypoglycemia can be increased when Nisoldipine is combined with Canagliflozin.The serum concentration of Norepinephrine can be increased when it is combined with Metformin.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Norethisterone.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Norgestimate.Nortriptyline may decrease the hypoglycemic activities of Metformin.The therapeutic efficacy of Metformin can be decreased when used in combination with Octreotide.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Octreotide.The therapeutic efficacy of Metformin can be increased when used in combination with Ofloxacin.The therapeutic efficacy of Canagliflozin can be increased when used in combination with Ofloxacin.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Olanzapine.The risk or severity of hypotension, hyperkalemia, and reduced intravascular volume can be increased when Canagliflozin is combined with Olmesartan.Olsalazine may increase the hypoglycemic activities of Metformin.Olsalazine may increase the hypoglycemic activities of Canagliflozin.The serum concentration of Omadacycline can be increased when it is combined with Canagliflozin.The serum concentration of Ombitasvir can be increased when it is combined with Canagliflozin.The serum concentration of Canagliflozin can be increased when it is combined with Pacritinib.The serum concentration of Canagliflozin can be increased when it is combined with Palbociclib.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Paliperidone.The serum concentration of Paritaprevir can be increased when it is combined with Canagliflozin.The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Metformin.The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Canagliflozin.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Pasireotide.Patiromer can cause a decrease in the absorption of Metformin resulting in a reduced serum concentration and potentially a decrease in efficacy.The serum concentration of Pazopanib can be increased when it is combined with Canagliflozin.The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Metformin.The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Canagliflozin.Metformin may decrease the excretion rate of Pemetrexed which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Pemetrexed which could result in a higher serum level.Canagliflozin may increase the hypoglycemic activities of Pentamidine.The serum concentration of Canagliflozin can be decreased when it is combined with Pentobarbital.Metformin may decrease the excretion rate of Pentostatin which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Pentostatin which could result in a higher serum level.The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Canagliflozin is combined with Perindopril.The excretion of Metformin can be decreased when combined with Pexidartinib.Phenelzine may increase the orthostatic hypotensive activities of Canagliflozin.The serum concentration of Canagliflozin can be decreased when it is combined with Phenobarbital.The serum concentration of Metformin can be increased when it is combined with Phenoxybenzamine.The therapeutic efficacy of Metformin can be increased when used in combination with Phentermine.The therapeutic efficacy of Canagliflozin can be increased when used in combination with Phentermine.The serum concentration of Canagliflozin can be decreased when it is combined with Phenytoin.The serum concentration of Pibrentasvir can be increased when it is combined with Canagliflozin.The risk or severity of hypoglycemia can be increased when Pinaverium is combined with Metformin.The risk or severity of hypoglycemia can be increased when Pinaverium is combined with Canagliflozin.The therapeutic efficacy of Metformin can be increased when used in combination with Pindolol.The therapeutic efficacy of Canagliflozin can be increased when used in combination with Pindolol.Canagliflozin may increase the hypoglycemic activities of Pioglitazone.The serum concentration of Canagliflozin can be increased when it is combined with Piperine.The serum concentration of Canagliflozin can be increased when it is combined with Pirtobrutinib.The serum concentration of Canagliflozin can be decreased when it is combined with Pitolisant.Metformin may decrease the excretion rate of Plazomicin which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Plazomicin which could result in a higher serum level.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Polythiazide.The serum concentration of Canagliflozin can be increased when it is combined with Ponatinib.Potassium may increase the hyperkalemic activities of Canagliflozin.Potassium acetate may increase the hyperkalemic activities of Canagliflozin.Potassium bicarbonate may increase the hyperkalemic activities of Canagliflozin.Potassium bitartrate may increase the hyperkalemic activities of Canagliflozin.Potassium carbonate may increase the hyperkalemic activities of Canagliflozin.Potassium cation may increase the hyperkalemic activities of Canagliflozin.Potassium chloride may increase the hyperkalemic activities of Canagliflozin.Potassium citrate may increase the hyperkalemic activities of Canagliflozin.Potassium hydroxide may increase the hyperkalemic activities of Canagliflozin.Potassium Iodide may increase the hyperkalemic activities of Canagliflozin.Potassium nitrate may increase the hyperkalemic activities of Canagliflozin.Potassium sulfate may increase the hyperkalemic activities of Canagliflozin.Potassium triiodide may increase the hyperkalemic activities of Canagliflozin.The excretion of Metformin can be decreased when combined with Pralsetinib.The serum concentration of Pralsetinib can be increased when it is combined with Canagliflozin.The risk or severity of hypoglycemia can be increased when Pramlintide is combined with Metformin.Canagliflozin may increase the hypoglycemic activities of Pramlintide.The serum concentration of Pravastatin can be increased when it is combined with Canagliflozin.The risk or severity of hyperglycemia can be increased when Prednicarbate is combined with Metformin.The risk or severity of hyperglycemia can be increased when Prednicarbate is combined with Canagliflozin.The risk or severity of hyperglycemia can be increased when Prednisolone is combined with Canagliflozin.The risk or severity of hyperglycemia can be increased when Prednisolone acetate is combined with Metformin.The risk or severity of hyperglycemia can be increased when Prednisolone acetate is combined with Canagliflozin.The risk or severity of hyperglycemia can be increased when Prednisolone phosphate is combined with Metformin.The risk or severity of hyperglycemia can be increased when Prednisolone phosphate is combined with Canagliflozin.The risk or severity of hyperglycemia can be increased when Prednisone is combined with Canagliflozin.The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Metformin.The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Canagliflozin.The serum concentration of Canagliflozin can be increased when it is combined with Pretomanid.The metabolism of Canagliflozin can be decreased when combined with Primaquine.The serum concentration of Canagliflozin can be decreased when it is combined with Primidone.The serum concentration of Metformin can be increased when it is combined with Probenecid.Canagliflozin may decrease the excretion rate of Procainamide which could result in a higher serum level.Procaine may increase the orthostatic hypotensive activities of Canagliflozin.Procarbazine may increase the orthostatic hypotensive activities of Canagliflozin.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Progesterone.The therapeutic efficacy of Metformin can be increased when used in combination with Propafenone.The therapeutic efficacy of Canagliflozin can be increased when used in combination with Propafenone.The therapeutic efficacy of Metformin can be increased when used in combination with Propranolol.The therapeutic efficacy of Canagliflozin can be increased when used in combination with Propranolol.Protriptyline may decrease the hypoglycemic activities of Metformin.Protriptyline may decrease the hypoglycemic activities of Canagliflozin.The serum concentration of Prucalopride can be increased when it is combined with Canagliflozin.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Pseudoephedrine.The excretion of Metformin can be decreased when combined with Pyrimethamine.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Quetiapine.The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Canagliflozin is combined with Quinapril.Metformin may decrease the excretion rate of Quinidine which could result in a higher serum level.The risk or severity of hypoglycemia can be increased when Quinine is combined with Metformin.Canagliflozin may increase the hypoglycemic activities of Quinine.The serum concentration of Quizartinib can be increased when it is combined with Canagliflozin.The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Canagliflozin is combined with Ramipril.The serum concentration of Ranitidine can be increased when it is combined with Metformin.The serum concentration of Metformin can be increased when it is combined with Ranolazine.The serum concentration of Ranolazine can be increased when it is combined with Canagliflozin.Rasagiline may increase the orthostatic hypotensive activities of Canagliflozin.The excretion of Relebactam can be decreased when combined with Metformin.The serum concentration of Relugolix can be increased when it is combined with Canagliflozin.Canagliflozin may increase the hypoglycemic activities of Repaglinide.The excretion of Metformin can be decreased when combined with Repotrectinib.The serum concentration of Repotrectinib can be increased when it is combined with Canagliflozin.The serum concentration of Canagliflozin can be increased when it is combined with Reserpine.The serum concentration of Revefenacin can be increased when it is combined with Canagliflozin.The serum concentration of Canagliflozin can be decreased when it is combined with Rifampicin.The serum concentration of Rifaximin can be increased when it is combined with Canagliflozin.The serum concentration of Riociguat can be increased when it is combined with Canagliflozin.The serum concentration of Ripretinib can be increased when it is combined with Canagliflozin.The serum concentration of Metformin can be increased when it is combined with Risdiplam.The serum concentration of Canagliflozin can be increased when it is combined with Ritlecitinib.The metabolism of Canagliflozin can be increased when combined with Ritonavir.The serum concentration of Rivaroxaban can be increased when it is combined with Canagliflozin.The serum concentration of Canagliflozin can be increased when it is combined with Rolapitant.Canagliflozin may increase the hypoglycemic activities of Rosiglitazone.Safinamide may increase the orthostatic hypotensive activities of Canagliflozin.Salicylic acid may increase the hypoglycemic activities of Metformin.Salicylic acid may increase the hypoglycemic activities of Canagliflozin.The serum concentration of Metformin can be increased when it is combined with Salmeterol.The serum concentration of Canagliflozin can be increased when it is combined with Sapropterin.The serum concentration of Canagliflozin can be increased when it is combined with Sarecycline.The serum concentration of Canagliflozin can be decreased when it is combined with Satralizumab.Canagliflozin may increase the hypoglycemic activities of Saxagliptin.The serum concentration of Canagliflozin can be decreased when it is combined with Secobarbital.Selegiline may increase the orthostatic hypotensive activities of Canagliflozin.The serum concentration of Selexipag can be increased when it is combined with Canagliflozin.The serum concentration of Selumetinib can be increased when it is combined with Canagliflozin.The risk or severity of hypoglycemia can be increased when Metformin is combined with Semaglutide.Canagliflozin may increase the hypoglycemic activities of Semaglutide.The risk or severity of hypoglycemia can be increased when Sertraline is combined with Metformin.The risk or severity of hypoglycemia can be increased when Sertraline is combined with Canagliflozin.The serum concentration of Canagliflozin can be increased when it is combined with Sildenafil.The serum concentration of Canagliflozin can be increased when it is combined with Simvastatin.Canagliflozin may increase the hypoglycemic activities of Sitagliptin.The risk or severity of hypotension can be increased when Sodium ferric gluconate complex is combined with Canagliflozin.Sodium phosphate, monobasic may increase the hyperkalemic activities of Canagliflozin.The serum concentration of Sofosbuvir can be increased when it is combined with Canagliflozin.The therapeutic efficacy of Metformin can be decreased when used in combination with Somapacitan.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Somapacitan.Somatotropin may decrease the hypoglycemic activities of Metformin.Somatotropin may decrease the hypoglycemic activities of Canagliflozin.The therapeutic efficacy of Metformin can be decreased when used in combination with Somatrogon.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Somatrogon.The serum concentration of Canagliflozin can be increased when it is combined with Sorafenib.The risk or severity of hypoglycemia can be increased when Metformin is combined with Sotagliflozin.Canagliflozin may increase the hypoglycemic activities of Sotagliflozin.The risk or severity of hypoglycemia can be increased when Sotalol is combined with Metformin.The risk or severity of hypoglycemia can be increased when Sotalol is combined with Canagliflozin.The serum concentration of Canagliflozin can be decreased when it is combined with Sotorasib.The risk or severity of hypotension, hyperkalemia, and reduced intravascular volume can be increased when Canagliflozin is combined with Sparsentan.The metabolism of Canagliflozin can be decreased when combined with Stiripentol.Metformin may decrease the excretion rate of Streptomycin which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Streptomycin which could result in a higher serum level.The risk or severity of hypoglycemia can be increased when Sulfadiazine is combined with Metformin.Canagliflozin may increase the hypoglycemic activities of Sulfadiazine.The risk or severity of hypoglycemia can be increased when Sulfamethoxazole is combined with Metformin.Canagliflozin may increase the hypoglycemic activities of Sulfamethoxazole.Sulfasalazine may increase the hypoglycemic activities of Metformin.Sulfasalazine may increase the hypoglycemic activities of Canagliflozin.The risk or severity of hypoglycemia can be increased when Sunitinib is combined with Metformin.Canagliflozin may increase the hypoglycemic activities of Sunitinib.The serum concentration of Canagliflozin can be increased when it is combined with Suvorexant.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Tacrolimus.The serum concentration of Metformin can be increased when it is combined with Tafenoquine.The serum concentration of Canagliflozin can be increased when it is combined with Tamoxifen.The excretion of Metformin can be decreased when combined with Tazemetostat.The serum concentration of Tazemetostat can be increased when it is combined with Canagliflozin.The serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Canagliflozin.The serum concentration of Tegaserod can be increased when it is combined with Canagliflozin.The risk or severity of hypotension, hyperkalemia, and reduced intravascular volume can be increased when Canagliflozin is combined with Telmisartan.The serum concentration of Canagliflozin can be decreased when it is combined with Telotristat ethyl.The serum concentration of Tenofovir alafenamide can be increased when it is combined with Metformin.The serum concentration of Tenofovir alafenamide can be increased when it is combined with Canagliflozin.The serum concentration of Tenofovir disoproxil can be increased when it is combined with Canagliflozin.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Teprotumumab.The serum concentration of Tezacaftor can be increased when it is combined with Canagliflozin.The serum concentration of Metformin can be increased when it is combined with Thiamine.The therapeutic efficacy of Metformin can be decreased when used in combination with Thyroid, porcine.Thyroid, porcine may decrease the hypoglycemic activities of Canagliflozin.The therapeutic efficacy of Metformin can be decreased when used in combination with Thyrotropin alfa.Thyrotropin alfa may decrease the hypoglycemic activities of Canagliflozin.The serum concentration of Canagliflozin can be increased when it is combined with Ticagrelor.The therapeutic efficacy of Metformin can be increased when used in combination with Timolol.The therapeutic efficacy of Canagliflozin can be increased when used in combination with Timolol.The risk or severity of hypoglycemia can be increased when Metformin is combined with Tirzepatide.Canagliflozin may increase the hypoglycemic activities of Tirzepatide.The serum concentration of Tivozanib can be increased when it is combined with Canagliflozin.The risk or severity of hyperglycemia can be increased when Tixocortol is combined with Metformin.The risk or severity of hyperglycemia can be increased when Tixocortol is combined with Canagliflozin.Metformin may decrease the excretion rate of Tobramycin which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Tobramycin which could result in a higher serum level.The risk or severity of hypoglycemia can be increased when Tolazamide is combined with Metformin.Canagliflozin may increase the hypoglycemic activities of Tolazamide.The risk or severity of lactic acidosis can be increased when Topiramate is combined with Metformin.The serum concentration of Topotecan can be increased when it is combined with Canagliflozin.The risk or severity of hypotension can be increased when Canagliflozin is combined with Torasemide.The serum concentration of Canagliflozin can be increased when it is combined with Toremifene.The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Canagliflozin is combined with Trandolapril.Tranylcypromine may increase the orthostatic hypotensive activities of Canagliflozin.The risk or severity of hyperglycemia can be increased when Triamcinolone is combined with Canagliflozin.The serum concentration of Metformin can be increased when it is combined with Trilaciclib.The serum concentration of Trilaciclib can be increased when it is combined with Canagliflozin.The serum concentration of Metformin can be increased when it is combined with Trimethoprim.Trimipramine may decrease the hypoglycemic activities of Metformin.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Triptorelin.Trolamine salicylate may increase the hypoglycemic activities of Metformin.Trolamine salicylate may increase the hypoglycemic activities of Canagliflozin.The therapeutic efficacy of Metformin can be increased when used in combination with Trovafloxacin.The therapeutic efficacy of Canagliflozin can be increased when used in combination with Trovafloxacin.The serum concentration of Metformin can be increased when it is combined with Tucatinib.Tucatinib may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Metformin.The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Canagliflozin.The serum concentration of Ubrogepant can be increased when it is combined with Canagliflozin.The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Metformin.The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Canagliflozin.The serum concentration of Umeclidinium can be increased when it is combined with Canagliflozin.The risk or severity of hypotension, hyperkalemia, and reduced intravascular volume can be increased when Canagliflozin is combined with Valsartan.The risk or severity of hyperglycemia can be increased when Vamorolone is combined with Metformin.The risk or severity of hyperglycemia can be increased when Vamorolone is combined with Canagliflozin.Metformin may decrease the excretion rate of Vancomycin which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Vancomycin which could result in a higher serum level.The serum concentration of Metformin can be increased when it is combined with Vandetanib.The serum concentration of Canagliflozin can be increased when it is combined with Vandetanib.The serum concentration of Canagliflozin can be increased when it is combined with Vardenafil.The serum concentration of Metformin can be increased when it is combined with Varenicline.The serum concentration of Velpatasvir can be increased when it is combined with Canagliflozin.The serum concentration of Canagliflozin can be increased when it is combined with Vemurafenib.The risk or severity of hypoglycemia can be increased when Venlafaxine is combined with Metformin.The risk or severity of hypoglycemia can be increased when Venlafaxine is combined with Canagliflozin.The risk or severity of hypoglycemia can be increased when Verapamil is combined with Metformin.The metabolism of Canagliflozin can be decreased when combined with Verapamil.The serum concentration of Metformin can be increased when it is combined with Vimseltinib.The serum concentration of Canagliflozin can be increased when it is combined with Vimseltinib.The excretion of Vincristine can be decreased when combined with Canagliflozin.The serum concentration of Voclosporin can be increased when it is combined with Canagliflozin.The serum concentration of Canagliflozin can be increased when it is combined with Vorapaxar.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Vorinostat.The serum concentration of Voxilaprevir can be increased when it is combined with Canagliflozin.Metformin may decrease the excretion rate of Warfarin which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Warfarin which could result in a higher serum level.The risk or severity of hypoglycemia can be increased when Xylometazoline is combined with Metformin.The risk or severity of hypoglycemia can be increased when Xylometazoline is combined with Canagliflozin.The risk or severity of hypoglycemia can be increased when Ziconotide is combined with Metformin.The risk or severity of hypoglycemia can be increased when Ziconotide is combined with Canagliflozin.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Ziprasidone.The risk or severity of lactic acidosis can be increased when Zonisamide is combined with Metformin.The serum concentration of Canagliflozin can be increased when it is combined with Zonisamide.Metformin may decrease the excretion rate of Abacavir which could result in a higher serum level.Abacavir may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The risk or severity of adverse effects can be increased when Abaloparatide is combined with Canagliflozin.The serum concentration of Metformin can be decreased when it is combined with Acarbose.Aceclofenac may decrease the excretion rate of Metformin which could result in a higher serum level.The risk or severity of hyperkalemia can be increased when Aceclofenac is combined with Canagliflozin.Acetaminophen may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The therapeutic efficacy of Canagliflozin can be increased when used in combination with Acetazolamide.The therapeutic efficacy of Metformin can be increased when used in combination with Acetyl sulfisoxazole.The therapeutic efficacy of Canagliflozin can be increased when used in combination with Acetyl sulfisoxazole.Metformin may decrease the excretion rate of Aclidinium which could result in a higher serum level.Aclidinium may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Metformin may decrease the excretion rate of Acrivastine which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Acrivastine which could result in a higher serum level.Acyclovir may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Adefovir dipivoxil may decrease the excretion rate of Metformin which could result in a higher serum level.Adefovir dipivoxil may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Albuterol.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Albuterol.Metformin may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level.Aldesleukin may decrease the excretion rate of Metformin which could result in a higher serum level.The risk or severity of adverse effects can be increased when Aldesleukin is combined with Canagliflozin.The risk or severity of adverse effects can be increased when Canagliflozin is combined with Aliskiren.Metformin may decrease the excretion rate of Allopurinol which could result in a higher serum level.Allopurinol may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Metformin may decrease the excretion rate of Almasilate which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Almasilate which could result in a higher serum level.Metformin may decrease the excretion rate of Almotriptan which could result in a higher serum level.Almotriptan may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Metformin may decrease the excretion rate of Alprazolam which could result in a higher serum level.Alprazolam may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Amantadine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The risk or severity of adverse effects can be increased when Amifostine is combined with Canagliflozin.The risk or severity of adverse effects can be increased when Amiloride is combined with Canagliflozin.Metformin may decrease the excretion rate of Ammonium chloride which could result in a higher serum level.The risk or severity of hyperkalemia can be increased when Ammonium chloride is combined with Canagliflozin.Metformin may decrease the excretion rate of Amoxicillin which could result in a higher serum level.Amoxicillin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Amphetamine may decrease the excretion rate of Metformin which could result in a higher serum level.Amphetamine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Amphotericin B may decrease the excretion rate of Metformin which could result in a higher serum level.The risk or severity of adverse effects can be increased when Amphotericin B is combined with Canagliflozin.Metformin may decrease the excretion rate of Ampicillin which could result in a higher serum level.Ampicillin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Canagliflozin.Antipyrine may decrease the excretion rate of Metformin which could result in a higher serum level.The risk or severity of hyperkalemia can be increased when Antipyrine is combined with Canagliflozin.Metformin may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.The risk or severity of adverse effects can be increased when Apomorphine is combined with Canagliflozin.Metformin may decrease the excretion rate of Apremilast which could result in a higher serum level.Apremilast may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Canagliflozin may increase the hypotensive activities of Aprocitentan.Metformin may decrease the excretion rate of Arformoterol which could result in a higher serum level.Arformoterol may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The serum concentration of Metformin can be increased when it is combined with Arimoclomol.The therapeutic efficacy of Metformin can be decreased when used in combination with Aripiprazole.Aripiprazole lauroxil may increase the hypotensive activities of Canagliflozin.The therapeutic efficacy of Metformin can be decreased when used in combination with Arsenic trioxide.The therapeutic efficacy of Metformin can be decreased when used in combination with Articaine.The therapeutic efficacy of Metformin can be decreased when used in combination with Asenapine.The therapeutic efficacy of Metformin can be decreased when used in combination with Atazanavir.Atomoxetine may decrease the excretion rate of Metformin which could result in a higher serum level.Atomoxetine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Metformin may increase the hypolipidaemic activities of Atorvastatin.Metformin may decrease the excretion rate of Auranofin which could result in a higher serum level.Auranofin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Metformin may decrease the excretion rate of Azacitidine which could result in a higher serum level.Azacitidine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Metformin may decrease the excretion rate of Azathioprine which could result in a higher serum level.Azathioprine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Metformin may decrease the excretion rate of Azelaic acid which could result in a higher serum level.Azelaic acid may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Metformin may decrease the excretion rate of Aztreonam which could result in a higher serum level.Aztreonam may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Bacitracin may decrease the excretion rate of Metformin which could result in a higher serum level.Bacitracin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Baricitinib which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Beclomethasone dipropionate.The therapeutic efficacy of Metformin can be decreased when used in combination with Bendroflumethiazide.Benzatropine may decrease the excretion rate of Metformin which could result in a higher serum level.Benzatropine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Metformin may decrease the excretion rate of Benznidazole which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Benznidazole which could result in a higher serum level.Metformin may decrease the excretion rate of Bepotastine which could result in a higher serum level.Bepotastine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Betamethasone.Metformin may decrease the excretion rate of Bicisate which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Bicisate which could result in a higher serum level.The excretion of Metformin can be decreased when combined with Bictegravir.Metformin may decrease the excretion rate of Bismuth subgallate which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Bismuth subgallate which could result in a higher serum level.Bleomycin may decrease the excretion rate of Metformin which could result in a higher serum level.Bleomycin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The therapeutic efficacy of Metformin can be increased when used in combination with Bosentan.The therapeutic efficacy of Canagliflozin can be increased when used in combination with Bosentan.The risk or severity of adverse effects can be increased when Bretylium is combined with Canagliflozin.The therapeutic efficacy of Metformin can be decreased when used in combination with Brexpiprazole.Metformin may decrease the excretion rate of Brivaracetam which could result in a higher serum level.Brivaracetam may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Bromotheophylline may increase the excretion rate of Metformin which could result in a lower serum level and potentially a reduction in efficacy.Bromotheophylline may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.The therapeutic efficacy of Metformin can be decreased when used in combination with Bumetanide.The risk or severity of adverse effects can be increased when Bupivacaine is combined with Canagliflozin.Bupropion may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Metformin may decrease the excretion rate of Buspirone which could result in a higher serum level.Buspirone may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Metformin may decrease the excretion rate of Capecitabine which could result in a higher serum level.Capecitabine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The risk or severity of lactic acidosis can be increased when Captopril is combined with Metformin.Carbidopa may decrease the excretion rate of Metformin which could result in a higher serum level.Carbidopa may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Carboplatin may decrease the excretion rate of Metformin which could result in a higher serum level.Carboplatin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Carmustine may decrease the excretion rate of Metformin which could result in a higher serum level.Carmustine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Cefaclor may decrease the excretion rate of Metformin which could result in a higher serum level.Cefaclor may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Cefadroxil may decrease the excretion rate of Metformin which could result in a higher serum level.Cefadroxil may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Cefazolin may decrease the excretion rate of Metformin which could result in a higher serum level.Cefazolin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Metformin may decrease the excretion rate of Cefdinir which could result in a higher serum level.Cefdinir may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Cefditoren may decrease the excretion rate of Metformin which could result in a higher serum level.Cefditoren may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Cefepime may decrease the excretion rate of Metformin which could result in a higher serum level.Cefepime may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Cefotaxime may decrease the excretion rate of Metformin which could result in a higher serum level.Cefotaxime may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Cefotetan may decrease the excretion rate of Metformin which could result in a higher serum level.Cefotetan may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Cefoxitin may decrease the excretion rate of Metformin which could result in a higher serum level.Cefoxitin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Cefpodoxime may decrease the excretion rate of Metformin which could result in a higher serum level.Cefpodoxime may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Cefprozil may decrease the excretion rate of Metformin which could result in a higher serum level.Cefprozil may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Ceftaroline fosamil may decrease the excretion rate of Metformin which could result in a higher serum level.Ceftaroline fosamil may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Ceftazidime may decrease the excretion rate of Metformin which could result in a higher serum level.Ceftazidime may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Ceftibuten may decrease the excretion rate of Metformin which could result in a higher serum level.Ceftibuten may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Ceftizoxime may decrease the excretion rate of Metformin which could result in a higher serum level.Ceftizoxime may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Metformin may decrease the excretion rate of Ceftolozane which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Ceftolozane which could result in a higher serum level.Ceftriaxone may decrease the excretion rate of Metformin which could result in a higher serum level.Ceftriaxone may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Cefuroxime may decrease the excretion rate of Metformin which could result in a higher serum level.Cefuroxime may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The therapeutic efficacy of Metformin can be increased when used in combination with Celecoxib.The risk or severity of hyperkalemia can be increased when Celecoxib is combined with Canagliflozin.Cephalexin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Ceritinib.Metformin may decrease the excretion rate of Certolizumab pegol which could result in a higher serum level.Certolizumab pegol may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Metformin may decrease the excretion rate of Cetirizine which could result in a higher serum level.Cetirizine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Cevimeline may decrease the excretion rate of Metformin which could result in a higher serum level.Cevimeline may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Metformin may decrease the excretion rate of Chloroquine which could result in a higher serum level.Chloroquine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Chlorothiazide.The therapeutic efficacy of Metformin can be decreased when used in combination with Chlorpromazine.The therapeutic efficacy of Metformin can be decreased when used in combination with Chlorthalidone.Metformin may decrease the excretion rate of Chlorzoxazone which could result in a higher serum level.Chlorzoxazone may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Metformin may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.Metformin may decrease the excretion rate of Chromic chloride which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Chromic chloride which could result in a higher serum level.Metformin may decrease the excretion rate of Chromium which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Chromium which could result in a higher serum level.Metformin may decrease the excretion rate of Chromium nicotinate which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Chromium nicotinate which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Ciclesonide.Cidofovir may decrease the excretion rate of Metformin which could result in a higher serum level.Cidofovir may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Metformin may decrease the excretion rate of Cilostazol which could result in a higher serum level.Cilostazol may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The serum concentration of Metformin can be increased when it is combined with Cimetidine.Cimetidine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Metformin may decrease the excretion rate of Clobazam which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Clobetasol propionate.Metformin may decrease the excretion rate of Clofarabine which could result in a higher serum level.The risk or severity of adverse effects can be increased when Clofarabine is combined with Canagliflozin.Metformin may decrease the excretion rate of Clonazepam which could result in a higher serum level.Clonazepam may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The risk or severity of adverse effects can be increased when Clonidine is combined with Canagliflozin.Metformin may decrease the excretion rate of Clorazepic acid which could result in a higher serum level.Clorazepic acid may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Metformin may decrease the excretion rate of Clove oil which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Clove oil which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Clozapine.Metformin may decrease the excretion rate of Colchicine which could result in a higher serum level.Colistimethate may decrease the excretion rate of Metformin which could result in a higher serum level.Colistimethate may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Conivaptan may increase the excretion rate of Metformin which could result in a lower serum level and potentially a reduction in efficacy.The therapeutic efficacy of Metformin can be decreased when used in combination with Corticotropin.The therapeutic efficacy of Metformin can be decreased when used in combination with Cortisone acetate.Cyanocobalamin may decrease the excretion rate of Metformin which could result in a higher serum level.Cyanocobalamin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Cyclosporine may decrease the excretion rate of Metformin which could result in a higher serum level.Metformin may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Dabrafenib.Metformin may decrease the excretion rate of Dacarbazine which could result in a higher serum level.Dacarbazine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The serum concentration of Dalfampridine can be increased when it is combined with Metformin.Dalfampridine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The risk or severity of hyperkalemia can be increased when Dalteparin is combined with Canagliflozin.The therapeutic efficacy of Metformin can be decreased when used in combination with Danazol.The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Canagliflozin.Daptomycin may decrease the excretion rate of Metformin which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Darunavir.Canagliflozin may increase the hypotensive activities of Dasiglucagon.Metformin may decrease the excretion rate of Deferiprone which could result in a higher serum level.Deferiprone may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Deflazacort.The risk or severity of adverse effects can be increased when Desflurane is combined with Canagliflozin.Desmopressin may decrease the excretion rate of Metformin which could result in a higher serum level.Desmopressin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Desogestrel.Metformin may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Dexamethasone.Metformin may decrease the excretion rate of Dexmedetomidine which could result in a higher serum level.The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Canagliflozin.Metformin may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.Metformin may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.Dexrazoxane may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Metformin may decrease the excretion rate of Dextran which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Dextran which could result in a higher serum level.Diatrizoate may decrease the excretion rate of Metformin which could result in a higher serum level.Diatrizoate may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Metformin may decrease the excretion rate of Diazepam which could result in a higher serum level.Diazepam may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Diazoxide.Diclofenac may decrease the excretion rate of Metformin which could result in a higher serum level.The risk or severity of hyperkalemia can be increased when Diclofenac is combined with Canagliflozin.The risk or severity of adverse effects can be increased when Diclofenamide is combined with Canagliflozin.Metformin may decrease the excretion rate of Dicyclomine which could result in a higher serum level.Dicyclomine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Metformin may decrease the excretion rate of Didanosine which could result in a higher serum level.Didanosine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Dienogest.Metformin may decrease the excretion rate of Dimercaprol which could result in a higher serum level.Dimercaprol may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Metformin may decrease the excretion rate of Dimethyl sulfoxide which could result in a higher serum level.Dimethyl sulfoxide may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The risk or severity of adverse effects can be increased when Canagliflozin is combined with Dinutuximab.The risk or severity of adverse effects can be increased when Dipyridamole is combined with Canagliflozin.Metformin may decrease the excretion rate of DL-Methylephedrine which could result in a higher serum level.Canagliflozin may decrease the excretion rate of DL-Methylephedrine which could result in a higher serum level.Metformin may decrease the excretion rate of Dobutamine which could result in a higher serum level.Dobutamine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Dopamine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The risk or severity of adverse effects can be increased when Doxazosin is combined with Canagliflozin.Doxycycline may decrease the excretion rate of Metformin which could result in a higher serum level.Doxycycline may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Drospirenone.Metformin may decrease the excretion rate of Droxidopa which could result in a higher serum level.Droxidopa may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The risk or severity of orthostatic hypotension and syncope can be increased when Canagliflozin is combined with Duloxetine.Metformin may decrease the excretion rate of Edoxaban which could result in a higher serum level.Metformin may decrease the excretion rate of Edrophonium which could result in a higher serum level.Edrophonium may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The excretion of Emtricitabine can be decreased when combined with Metformin.The risk or severity of lactic acidosis can be increased when Enalapril is combined with Metformin.The risk or severity of lactic acidosis can be increased when Enalaprilat is combined with Metformin.The risk or severity of hyperkalemia can be increased when Enoxaparin is combined with Canagliflozin.The serum concentration of Ensartinib can be increased when it is combined with Canagliflozin.Metformin may decrease the excretion rate of Enzalutamide which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Epinephrine.Eplerenone may increase the excretion rate of Metformin which could result in a lower serum level and potentially a reduction in efficacy.The risk or severity of adverse effects can be increased when Eplerenone is combined with Canagliflozin.Metformin may decrease the excretion rate of Epoprostenol which could result in a higher serum level.The risk or severity of adverse effects can be increased when Epoprostenol is combined with Canagliflozin.Ertapenem may decrease the excretion rate of Metformin which could result in a higher serum level.Ertapenem may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The risk or severity of adverse effects can be increased when Esmolol is combined with Canagliflozin.Metformin may decrease the excretion rate of Estazolam which could result in a higher serum level.Estazolam may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Estradiol.Canagliflozin may decrease the excretion rate of Estradiol acetate which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Estradiol cypionate which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Estradiol valerate which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Estrone sulfate.Metformin may decrease the excretion rate of Eszopiclone which could result in a higher serum level.Eszopiclone may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Etacrynic acid.Ethambutol may decrease the excretion rate of Metformin which could result in a higher serum level.Ethambutol may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Ethenzamide may decrease the excretion rate of Metformin which could result in a higher serum level.The risk or severity of hyperkalemia can be increased when Canagliflozin is combined with Ethenzamide.The therapeutic efficacy of Metformin can be decreased when used in combination with Ethinylestradiol.The therapeutic efficacy of Metformin can be decreased when used in combination with Ethynodiol diacetate.Etodolac may decrease the excretion rate of Metformin which could result in a higher serum level.The risk or severity of hyperkalemia can be increased when Etodolac is combined with Canagliflozin.Etomidate may decrease the excretion rate of Metformin which could result in a higher serum level.Etomidate may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Etonogestrel.Metformin may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.Metformin may decrease the excretion rate of Evening primrose oil which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Evening primrose oil which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Everolimus.Fenofibrate may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Metformin may decrease the excretion rate of Fenofibric acid which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Fenofibric acid which could result in a higher serum level.Metformin may decrease the excretion rate of Fenoldopam which could result in a higher serum level.The risk or severity of adverse effects can be increased when Fenoldopam is combined with Canagliflozin.Fenoprofen may decrease the excretion rate of Metformin which could result in a higher serum level.The risk or severity of hyperkalemia can be increased when Fenoprofen is combined with Canagliflozin.Metformin may decrease the excretion rate of Fentanyl which could result in a higher serum level.Fentanyl may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Metformin may decrease the excretion rate of Fesoterodine which could result in a higher serum level.Fesoterodine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Finerenone may increase the excretion rate of Metformin which could result in a lower serum level and potentially a reduction in efficacy.The risk or severity of hyperkalemia can be increased when Canagliflozin is combined with Finerenone.The risk or severity of hyperkalemia can be increased when Canagliflozin is combined with Fish oil.Metformin may decrease the excretion rate of Flavoxate which could result in a higher serum level.Flavoxate may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The excretion of Flecainide can be decreased when combined with Metformin.Metformin may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.Metformin may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.Floxuridine may decrease the excretion rate of Metformin which could result in a higher serum level.Floxuridine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Metformin may decrease the excretion rate of Flucytosine which could result in a higher serum level.Flucytosine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Metformin may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Fludrocortisone.Metformin may decrease the excretion rate of Flumazenil which could result in a higher serum level.Flumazenil may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Fluorometholone.Fluoxymesterone may increase the hypoglycemic activities of Metformin.Fluoxymesterone may increase the hypoglycemic activities of Canagliflozin.Flurazepam may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Flurbiprofen may decrease the excretion rate of Metformin which could result in a higher serum level.The risk or severity of hyperkalemia can be increased when Flurbiprofen is combined with Canagliflozin.Metformin may decrease the excretion rate of Flutamide which could result in a higher serum level.Flutamide may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Fluticasone furoate.Metformin may increase the hypolipidaemic activities of Fluvastatin.Folic acid may decrease the excretion rate of Metformin which could result in a higher serum level.Folic acid may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Metformin may decrease the excretion rate of Fomepizole which could result in a higher serum level.Fomepizole may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Metformin may decrease the excretion rate of Fondaparinux which could result in a higher serum level.Fondaparinux may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Fosamprenavir.Foscarnet may decrease the excretion rate of Metformin which could result in a higher serum level.Foscarnet may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Metformin may decrease the excretion rate of Fosfomycin which could result in a higher serum level.Fosfomycin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The risk or severity of lactic acidosis can be increased when Fosinopril is combined with Metformin.The risk or severity of hypotension can be increased when Fostamatinib is combined with Canagliflozin.The therapeutic efficacy of Metformin can be decreased when used in combination with Furosemide.Metformin may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.Gabapentin enacarbil may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Metformin may decrease the excretion rate of Gadobenic acid which could result in a higher serum level.Gadobenic acid may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Gadodiamide may decrease the excretion rate of Metformin which could result in a higher serum level.Gadodiamide may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Metformin may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.Gadofosveset trisodium may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Metformin may decrease the excretion rate of Gadoteric acid which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Gadoteric acid which could result in a higher serum level.Metformin may decrease the excretion rate of Gadoteridol which could result in a higher serum level.Gadoteridol may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Ganciclovir may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Metformin may decrease the excretion rate of Gemcitabine which could result in a higher serum level.Metformin may decrease the excretion rate of Gemfibrozil which could result in a higher serum level.Gemfibrozil may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The excretion of Metformin can be decreased when combined with Gilteritinib.Givosiran may decrease the excretion rate of Metformin which could result in a higher serum level.Givosiran may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Metformin may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level.The serum concentration of Metformin can be increased when it is combined with Glycopyrronium.Metformin may decrease the excretion rate of Golodirsen which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Golodirsen which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Goserelin.Metformin may decrease the excretion rate of Guanfacine which could result in a higher serum level.The risk or severity of adverse effects can be increased when Guanfacine is combined with Canagliflozin.The therapeutic efficacy of Metformin can be decreased when used in combination with Haloperidol.The risk or severity of hyperkalemia can be increased when Heparin is combined with Canagliflozin.The therapeutic efficacy of Metformin can be decreased when used in combination with Histrelin.Metformin may decrease the excretion rate of Hydralazine which could result in a higher serum level.The risk or severity of adverse effects can be increased when Hydralazine is combined with Canagliflozin.The therapeutic efficacy of Metformin can be decreased when used in combination with Hydrochlorothiazide.The therapeutic efficacy of Metformin can be decreased when used in combination with Hydrocortisone.Hydromorphone may decrease the excretion rate of Metformin which could result in a higher serum level.Hydromorphone may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Hydroxocobalamin may decrease the excretion rate of Metformin which could result in a higher serum level.Hydroxocobalamin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Metformin may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Hydroxyprogesterone caproate.Ibuprofen may decrease the excretion rate of Metformin which could result in a higher serum level.The risk or severity of hyperkalemia can be increased when Ibuprofen is combined with Canagliflozin.Ibutilide may decrease the excretion rate of Metformin which could result in a higher serum level.Ibutilide may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Metformin may decrease the excretion rate of Icatibant which could result in a higher serum level.Icatibant may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Icosapent may decrease the excretion rate of Metformin which could result in a higher serum level.The risk or severity of hyperkalemia can be increased when Icosapent is combined with Canagliflozin.Metformin may decrease the excretion rate of Idarucizumab which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Idarucizumab which could result in a higher serum level.Metformin may decrease the excretion rate of Ifosfamide which could result in a higher serum level.Ifosfamide may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Iloperidone.The risk or severity of adverse effects can be increased when Iloprost is combined with Canagliflozin.The therapeutic efficacy of Metformin can be decreased when used in combination with Indapamide.Metformin may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Indinavir.Metformin may decrease the excretion rate of Inositol which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Inositol which could result in a higher serum level.Inotersen may decrease the excretion rate of Metformin which could result in a higher serum level.Inotersen may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Metformin may decrease the excretion rate of Iobenguane sulfate I-123 which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Iobenguane sulfate I-123 which could result in a higher serum level.Iodixanol may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Metformin may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level.Ioflupane I-123 may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Iopromide which could result in a higher serum level.Metformin may decrease the excretion rate of Iothalamic acid which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Iothalamic acid which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Ioversol which could result in a higher serum level.Metformin may decrease the excretion rate of Ipecac which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Ipecac which could result in a higher serum level.Metformin may decrease the excretion rate of Ipilimumab which could result in a higher serum level.Ipilimumab may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Isocarboxazid may increase the hypoglycemic activities of Metformin.The risk or severity of adverse effects can be increased when Isoflurane is combined with Canagliflozin.The therapeutic efficacy of Metformin can be decreased when used in combination with Isoniazid.Isosorbide may increase the excretion rate of Metformin which could result in a lower serum level and potentially a reduction in efficacy.Isosorbide may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.The risk or severity of adverse effects can be increased when Isosorbide dinitrate is combined with Canagliflozin.Metformin may decrease the excretion rate of Isosorbide mononitrate which could result in a higher serum level.The risk or severity of adverse effects can be increased when Isosorbide mononitrate is combined with Canagliflozin.Metformin may decrease the excretion rate of Isosulfan blue which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Isosulfan blue which could result in a higher serum level.Metformin may decrease the excretion rate of Isotretinoin which could result in a higher serum level.Isotretinoin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The risk or severity of adverse effects can be increased when Canagliflozin is combined with Isoxsuprine.Metformin may decrease the excretion rate of Ixazomib which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Ixazomib which could result in a higher serum level.Metformin may decrease the excretion rate of Ketamine which could result in a higher serum level.Ketamine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Ketoprofen may decrease the excretion rate of Metformin which could result in a higher serum level.The risk or severity of hyperkalemia can be increased when Ketoprofen is combined with Canagliflozin.Ketorolac may decrease the excretion rate of Metformin which could result in a higher serum level.The risk or severity of hyperkalemia can be increased when Ketorolac is combined with Canagliflozin.The risk or severity of thrombocytopenia can be increased when Metformin is combined with Ketotifen.The risk or severity of thrombocytopenia can be increased when Canagliflozin is combined with Ketotifen.The serum concentration of Canagliflozin can be increased when it is combined with L-Acetylleucine.Metformin may decrease the excretion rate of Lamivudine which could result in a higher serum level.Lamivudine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The serum concentration of Metformin can be increased when it is combined with Lamotrigine.The risk or severity of hyperkalemia can be increased when Lamotrigine is combined with Canagliflozin.The risk or severity of hyperkalemia can be increased when Canagliflozin is combined with Landiolol.The therapeutic efficacy of Metformin can be decreased when used in combination with Lanreotide.Metformin may decrease the excretion rate of Ledipasvir which could result in a higher serum level.Metformin may decrease the excretion rate of Lenalidomide which could result in a higher serum level.Lenalidomide may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Leuprolide.Metformin may decrease the excretion rate of Levocarnitine which could result in a higher serum level.Levocarnitine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Metformin may decrease the excretion rate of Levocetirizine which could result in a higher serum level.Levocetirizine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The risk or severity of hypotension and orthostatic hypotension can be increased when Canagliflozin is combined with Levodopa.The risk or severity of hyperkalemia can be increased when Levomenthol is combined with Canagliflozin.The therapeutic efficacy of Metformin can be decreased when used in combination with Levonorgestrel.Metformin may decrease the excretion rate of Levosalbutamol which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Levosalbutamol which could result in a higher serum level.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Levothyroxine.Linezolid may increase the hypoglycemic activities of Metformin.The risk or severity of lactic acidosis can be increased when Lisinopril is combined with Metformin.The therapeutic efficacy of Metformin can be decreased when used in combination with Lithium carbonate.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Lithium carbonate.Lithium citrate may decrease the excretion rate of Metformin which could result in a higher serum level.Lithium citrate may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Metformin may decrease the excretion rate of Lofexidine which could result in a higher serum level.The risk or severity of adverse effects can be increased when Lofexidine is combined with Canagliflozin.The excretion of Loperamide can be decreased when combined with Canagliflozin.The therapeutic efficacy of Metformin can be decreased when used in combination with Lopinavir.Lorazepam may decrease the excretion rate of Metformin which could result in a higher serum level.Lorazepam may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Metformin may increase the hypolipidaemic activities of Lovastatin.Metformin may decrease the excretion rate of Lubiprostone which could result in a higher serum level.Lubiprostone may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Lurasidone.Metformin may decrease the excretion rate of Macitentan which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Macitentan which could result in a higher serum level.Metformin may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level.Metformin may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.Metformin may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.Magnesium salicylate may decrease the excretion rate of Metformin which could result in a higher serum level.The risk or severity of hyperkalemia can be increased when Magnesium salicylate is combined with Canagliflozin.Metformin may decrease the excretion rate of Magnesium trisilicate which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Magnesium trisilicate which could result in a higher serum level.Mannitol may decrease the excretion rate of Metformin which could result in a higher serum level.Metformin may decrease the excretion rate of Maprotiline which could result in a higher serum level.Maprotiline may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Metformin may decrease the excretion rate of Mecamylamine which could result in a higher serum level.The risk or severity of adverse effects can be increased when Mecamylamine is combined with Canagliflozin.Meclofenamic acid may decrease the excretion rate of Metformin which could result in a higher serum level.The risk or severity of hyperkalemia can be increased when Meclofenamic acid is combined with Canagliflozin.The therapeutic efficacy of Metformin can be decreased when used in combination with Medroxyprogesterone acetate.Mefenamic acid may decrease the excretion rate of Metformin which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Megestrol acetate.Meloxicam may decrease the excretion rate of Metformin which could result in a higher serum level.The risk or severity of hyperkalemia can be increased when Meloxicam is combined with Canagliflozin.Metformin may decrease the excretion rate of Memantine which could result in a higher serum level.Memantine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Metformin may decrease the excretion rate of Meperidine which could result in a higher serum level.Meperidine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Metformin may decrease the excretion rate of Mepivacaine which could result in a higher serum level.Mepivacaine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Metformin may decrease the excretion rate of Meropenem which could result in a higher serum level.Meropenem may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Metformin may decrease the excretion rate of Metamfetamine which could result in a higher serum level.Metamfetamine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Metformin may decrease the excretion rate of Metaxalone which could result in a higher serum level.Metaxalone may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Metformin may decrease the excretion rate of Methadone which could result in a higher serum level.Methadone may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The risk or severity of adverse effects can be increased when Methazolamide is combined with Canagliflozin.Metformin may decrease the excretion rate of Methimazole which could result in a higher serum level.Methotrexate may decrease the excretion rate of Metformin which could result in a higher serum level.Methotrexate may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Metformin may decrease the excretion rate of Methoxsalen which could result in a higher serum level.Methoxsalen may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Metformin may decrease the excretion rate of Methyldopa which could result in a higher serum level.The risk or severity of adverse effects can be increased when Methyldopa is combined with Canagliflozin.Metformin may decrease the excretion rate of Methylnaltrexone which could result in a higher serum level.Methylnaltrexone may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Methylprednisolone.Methyltestosterone may increase the hypoglycemic activities of Metformin.Methyltestosterone may increase the hypoglycemic activities of Canagliflozin.Metformin may decrease the excretion rate of Metoclopramide which could result in a higher serum level.Metoclopramide may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Metolazone.The metabolism of Canagliflozin can be increased when combined with Metreleptin.Metformin may decrease the excretion rate of Metyrapone which could result in a higher serum level.Metyrapone may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Canagliflozin may increase the hypotensive activities of Metyrosine.Metformin may decrease the excretion rate of Midazolam which could result in a higher serum level.Metformin may decrease the excretion rate of Migalastat which could result in a higher serum level.Migalastat may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Milrinone may decrease the excretion rate of Metformin which could result in a higher serum level.Milrinone may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The risk or severity of adverse effects can be increased when Minoxidil is combined with Canagliflozin.Metformin may decrease the excretion rate of Mirabegron which could result in a higher serum level.The therapeutic efficacy of Metformin can be increased when used in combination with Mitapivat.The risk or severity of lactic acidosis can be increased when Moexipril is combined with Metformin.The therapeutic efficacy of Metformin can be decreased when used in combination with Mometasone furoate.Metformin may decrease the excretion rate of Mycophenolate mofetil which could result in a higher serum level.Mycophenolate mofetil may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Metformin may decrease the excretion rate of Mycophenolic acid which could result in a higher serum level.Mycophenolic acid may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Metformin may decrease the excretion rate of N-acetyltyrosine which could result in a higher serum level.Canagliflozin may decrease the excretion rate of N-acetyltyrosine which could result in a higher serum level.The risk or severity of adverse effects can be increased when Nabilone is combined with Canagliflozin.Nabumetone may decrease the excretion rate of Metformin which could result in a higher serum level.The risk or severity of hyperkalemia can be increased when Nabumetone is combined with Canagliflozin.Metformin may decrease the excretion rate of Naldemedine which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Naldemedine which could result in a higher serum level.Metformin may decrease the excretion rate of Nalmefene which could result in a higher serum level.Nalmefene may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Metformin may decrease the excretion rate of Naloxone which could result in a higher serum level.Naloxone may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Nandrolone decanoate may increase the hypoglycemic activities of Metformin.Nandrolone decanoate may increase the hypoglycemic activities of Canagliflozin.Naproxen may decrease the excretion rate of Metformin which could result in a higher serum level.The risk or severity of hyperkalemia can be increased when Naproxen is combined with Canagliflozin.Metformin may decrease the excretion rate of Nedocromil which could result in a higher serum level.Nedocromil may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Nelfinavir.The therapeutic efficacy of Metformin can be decreased when used in combination with Niacin.The therapeutic efficacy of Metformin can be decreased when used in combination with Nilotinib.Metformin may decrease the excretion rate of Nilutamide which could result in a higher serum level.Nilutamide may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Metformin may decrease the excretion rate of Nitric Oxide which could result in a higher serum level.The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Canagliflozin.Metformin may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.The risk or severity of hyperkalemia can be increased when Nitrofurantoin is combined with Canagliflozin.The risk or severity of adverse effects can be increased when Nitroglycerin is combined with Canagliflozin.Nitroprusside may decrease the excretion rate of Metformin which could result in a higher serum level.The risk or severity of adverse effects can be increased when Nitroprusside is combined with Canagliflozin.The risk or severity of adverse effects can be increased when Canagliflozin is combined with Nitrous acid.The therapeutic efficacy of Metformin can be decreased when used in combination with Norethisterone.The therapeutic efficacy of Metformin can be decreased when used in combination with Norgestimate.The risk or severity of adverse effects can be increased when Canagliflozin is combined with Obinutuzumab.Metformin may decrease the excretion rate of Octinoxate which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Octinoxate which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Olanzapine.The serum concentration of Canagliflozin can be decreased when it is combined with Omaveloxolone.The risk or severity of adverse effects can be increased when Canagliflozin is combined with Opicapone.Metformin may decrease the excretion rate of Opium which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Opium which could result in a higher serum level.Oseltamivir may decrease the excretion rate of Metformin which could result in a higher serum level.Oseltamivir may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Metformin may decrease the excretion rate of Oxacillin which could result in a higher serum level.Oxacillin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Oxandrolone may increase the hypoglycemic activities of Metformin.Oxandrolone may increase the hypoglycemic activities of Canagliflozin.Oxaprozin may decrease the excretion rate of Metformin which could result in a higher serum level.The risk or severity of hyperkalemia can be increased when Oxaprozin is combined with Canagliflozin.Metformin may decrease the excretion rate of Oxazepam which could result in a higher serum level.Oxazepam may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Metformin may decrease the excretion rate of Oxybenzone which could result in a higher serum level.Oxybenzone may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Oxymetholone may increase the hypoglycemic activities of Metformin.Oxymetholone may increase the hypoglycemic activities of Canagliflozin.Metformin may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.The risk or severity of adverse effects can be increased when Paclitaxel is combined with Canagliflozin.The therapeutic efficacy of Metformin can be decreased when used in combination with Paliperidone.Metformin may decrease the excretion rate of Palonosetron which could result in a higher serum level.Palonosetron may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Pamidronic acid may decrease the excretion rate of Metformin which could result in a higher serum level.Pamidronic acid may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Pantoprazole may decrease the excretion rate of Metformin which could result in a higher serum level.Pantoprazole may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The risk or severity of adverse effects can be increased when Papaverine is combined with Canagliflozin.Parecoxib may decrease the excretion rate of Metformin which could result in a higher serum level.The risk or severity of hyperkalemia can be increased when Parecoxib is combined with Canagliflozin.Paromomycin may decrease the excretion rate of Metformin which could result in a higher serum level.Paromomycin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Pasireotide.The therapeutic efficacy of Metformin can be decreased when used in combination with Pentamidine.Metformin may decrease the excretion rate of Pentetic acid which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Pentetic acid which could result in a higher serum level.Pentobarbital may decrease the excretion rate of Metformin which could result in a higher serum level.Metformin may decrease the excretion rate of Pentoxifylline which could result in a higher serum level.Pentoxifylline may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The risk or severity of lactic acidosis can be increased when Perindopril is combined with Metformin.Metformin may decrease the excretion rate of Permethrin which could result in a higher serum level.Permethrin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Phenazopyridine may decrease the excretion rate of Metformin which could result in a higher serum level.Phenazopyridine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Phenelzine may increase the hypoglycemic activities of Metformin.The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Canagliflozin.The risk or severity of adverse effects can be increased when Phentolamine is combined with Canagliflozin.The therapeutic efficacy of Metformin can be decreased when used in combination with Phenytoin.Metformin may decrease the excretion rate of Phosphoric acid which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Phosphoric acid which could result in a higher serum level.Metformin may decrease the excretion rate of Phylloquinone which could result in a higher serum level.Phylloquinone may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Metformin may decrease the excretion rate of Picosulfuric acid which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Picosulfuric acid which could result in a higher serum level.Piperacillin may decrease the excretion rate of Metformin which could result in a higher serum level.Piperacillin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Piroxicam may decrease the excretion rate of Metformin which could result in a higher serum level.The risk or severity of hyperkalemia can be increased when Piroxicam is combined with Canagliflozin.Metformin may increase the hypolipidaemic activities of Pitavastatin.Metformin may decrease the excretion rate of Pitolisant which could result in a higher serum level.Metformin may decrease the excretion rate of Plerixafor which could result in a higher serum level.Plerixafor may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Polythiazide.Metformin may decrease the excretion rate of Pomalidomide which could result in a higher serum level.Potassium may increase the excretion rate of Metformin which could result in a lower serum level and potentially a reduction in efficacy.Metformin may decrease the excretion rate of Potassium acetate which could result in a higher serum level.Metformin may decrease the excretion rate of Potassium bicarbonate which could result in a higher serum level.Metformin may decrease the excretion rate of Potassium cation which could result in a higher serum level.Metformin may decrease the excretion rate of Potassium chloride which could result in a higher serum level.Potassium citrate may increase the excretion rate of Metformin which could result in a lower serum level and potentially a reduction in efficacy.Metformin may decrease the excretion rate of Potassium nitrate which could result in a higher serum level.Metformin may decrease the excretion rate of Potassium sulfate which could result in a higher serum level.Metformin may decrease the excretion rate of Pralatrexate which could result in a higher serum level.Pralatrexate may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Metformin may decrease the excretion rate of Pralidoxime which could result in a higher serum level.Pralidoxime may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Metformin may decrease the excretion rate of Pramipexole which could result in a higher serum level.The risk or severity of adverse effects can be increased when Pramipexole is combined with Canagliflozin.Metformin may decrease the excretion rate of Prasugrel which could result in a higher serum level.Prasugrel may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Metformin may increase the hypolipidaemic activities of Pravastatin.The risk or severity of adverse effects can be increased when Prazosin is combined with Canagliflozin.The therapeutic efficacy of Metformin can be decreased when used in combination with Prednisolone.The therapeutic efficacy of Metformin can be decreased when used in combination with Prednisone.The therapeutic efficacy of Canagliflozin can be increased when used in combination with Probenecid.Procaine may increase the hypoglycemic activities of Metformin.Metformin may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.Procarbazine may increase the hypoglycemic activities of Metformin.The therapeutic efficacy of Metformin can be decreased when used in combination with Progesterone.Metformin may decrease the excretion rate of Promethazine which could result in a higher serum level.Promethazine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Metformin may decrease the excretion rate of Propantheline which could result in a higher serum level.Propantheline may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The risk or severity of adverse effects can be increased when Propofol is combined with Canagliflozin.Propyphenazone may decrease the excretion rate of Metformin which could result in a higher serum level.The risk or severity of hyperkalemia can be increased when Canagliflozin is combined with Propyphenazone.Metformin may decrease the excretion rate of Prucalopride which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Pseudoephedrine.Metformin may decrease the excretion rate of Pyrantel which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Pyrantel which could result in a higher serum level.Metformin may decrease the excretion rate of Pyrazinamide which could result in a higher serum level.Pyrazinamide may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Pyridoxine may decrease the excretion rate of Metformin which could result in a higher serum level.Pyridoxine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Quetiapine.The risk or severity of lactic acidosis can be increased when Quinapril is combined with Metformin.Metformin may decrease the excretion rate of Rabeprazole which could result in a higher serum level.Rabeprazole may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Metformin may decrease the excretion rate of Ramelteon which could result in a higher serum level.Ramelteon may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The risk or severity of lactic acidosis can be increased when Ramipril is combined with Metformin.Ranitidine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Rasagiline may increase the hypoglycemic activities of Metformin.The excretion of Metformin can be decreased when combined with Remdesivir.The risk or severity of adverse effects can be increased when Remifentanil is combined with Canagliflozin.Reserpine may decrease the excretion rate of Metformin which could result in a higher serum level.Metformin may decrease the excretion rate of Resorcinol which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Resorcinol which could result in a higher serum level.Metformin may decrease the excretion rate of Ribavirin which could result in a higher serum level.Ribavirin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The excretion of Metformin can be decreased when combined with Ripretinib.The therapeutic efficacy of Metformin can be decreased when used in combination with Risperidone.Canagliflozin may increase the hypotensive activities of Risperidone.The therapeutic efficacy of Metformin can be decreased when used in combination with Ritonavir.Metformin may decrease the excretion rate of Rivaroxaban which could result in a higher serum level.Metformin may decrease the excretion rate of Rizatriptan which could result in a higher serum level.Rizatriptan may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Metformin may decrease the excretion rate of Roflumilast which could result in a higher serum level.Roflumilast may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The risk or severity of adverse effects can be increased when Ropinirole is combined with Canagliflozin.Ropivacaine may decrease the excretion rate of Metformin which could result in a higher serum level.The risk or severity of adverse effects can be increased when Ropivacaine is combined with Canagliflozin.The therapeutic efficacy of Canagliflozin can be increased when used in combination with Rosuvastatin.The risk or severity of adverse effects can be increased when Rotigotine is combined with Canagliflozin.Metformin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.Ruxolitinib may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Metformin may decrease the excretion rate of Sacubitril which could result in a higher serum level.The risk or severity of adverse effects can be increased when Canagliflozin is combined with Sacubitril.Safinamide may increase the hypoglycemic activities of Metformin.Salicylamide may decrease the excretion rate of Metformin which could result in a higher serum level.The risk or severity of hyperkalemia can be increased when Salicylamide is combined with Canagliflozin.Salmon calcitonin may decrease the excretion rate of Metformin which could result in a higher serum level.Salmon calcitonin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Salsalate may decrease the excretion rate of Metformin which could result in a higher serum level.The risk or severity of hyperkalemia can be increased when Salsalate is combined with Canagliflozin.The therapeutic efficacy of Metformin can be decreased when used in combination with Saquinavir.Metformin may decrease the excretion rate of Secobarbital which could result in a higher serum level.Selegiline may increase the hypoglycemic activities of Metformin.Metformin may decrease the excretion rate of Selenious acid which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Selenious acid which could result in a higher serum level.Metformin may decrease the excretion rate of Selenium which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Selenium which could result in a higher serum level.The excretion of Metformin can be decreased when combined with Selpercatinib.The risk or severity of adverse effects can be increased when Sevoflurane is combined with Canagliflozin.Metformin may increase the hypolipidaemic activities of Simvastatin.The therapeutic efficacy of Metformin can be decreased when used in combination with Sirolimus.Metformin may decrease the excretion rate of Sodium acetate which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Sodium acetate which could result in a higher serum level.Metformin may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.Metformin may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.Metformin may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.Metformin may decrease the excretion rate of Solriamfetol which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Solriamfetol which could result in a higher serum level.Metformin may decrease the excretion rate of Sorafenib which could result in a higher serum level.Metformin may decrease the excretion rate of Sorbitol which could result in a higher serum level.Sorbitol may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Canagliflozin may increase the hypotensive activities of Sotatercept.Spironolactone may increase the excretion rate of Metformin which could result in a lower serum level and potentially a reduction in efficacy.Metformin may decrease the excretion rate of Stiripentol which could result in a higher serum level.The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Canagliflozin.Metformin may decrease the excretion rate of Sucralfate which could result in a higher serum level.Sucralfate may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The risk or severity of adverse effects can be increased when Sufentanil is combined with Canagliflozin.Metformin may decrease the excretion rate of Sulbactam which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Sulbactam which could result in a higher serum level.The therapeutic efficacy of Metformin can be increased when used in combination with Sulfamethizole.The therapeutic efficacy of Canagliflozin can be increased when used in combination with Sulfamethizole.Sulindac may decrease the excretion rate of Metformin which could result in a higher serum level.The risk or severity of hyperkalemia can be increased when Sulindac is combined with Canagliflozin.The therapeutic efficacy of Metformin can be increased when used in combination with Sumatriptan.The therapeutic efficacy of Canagliflozin can be increased when used in combination with Sumatriptan.Metformin may decrease the excretion rate of Synthetic Conjugated Estrogens, A which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Synthetic Conjugated Estrogens, A which could result in a higher serum level.Metformin may decrease the excretion rate of Synthetic Conjugated Estrogens, B which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Synthetic Conjugated Estrogens, B which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Tacrolimus.Metformin may decrease the excretion rate of Tadalafil which could result in a higher serum level.Tadalafil may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The serum concentration of Talazoparib can be increased when it is combined with Canagliflozin.The therapeutic efficacy of Metformin can be increased when used in combination with Tamsulosin.The risk or severity of adverse effects can be increased when Tamsulosin is combined with Canagliflozin.Metformin may decrease the excretion rate of Tasimelteon which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Tasimelteon which could result in a higher serum level.Metformin may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.Metformin may decrease the excretion rate of Technetium Tc-99m pyrophosphate which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Technetium Tc-99m pyrophosphate which could result in a higher serum level.Metformin may decrease the excretion rate of Teduglutide which could result in a higher serum level.Teduglutide may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Metformin may decrease the excretion rate of Telavancin which could result in a higher serum level.Telavancin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Temazepam may decrease the excretion rate of Metformin which could result in a higher serum level.Temazepam may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Metformin may decrease the excretion rate of Temozolomide which could result in a higher serum level.Temozolomide may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Temsirolimus.Tenofovir disoproxil may decrease the excretion rate of Metformin which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Teprotumumab.The risk or severity of adverse effects can be increased when Terazosin is combined with Canagliflozin.Metformin may decrease the excretion rate of Terbutaline which could result in a higher serum level.Terbutaline may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Testosterone may increase the hypoglycemic activities of Metformin.Testosterone may increase the hypoglycemic activities of Canagliflozin.Testosterone cypionate may increase the hypoglycemic activities of Metformin.Testosterone cypionate may increase the hypoglycemic activities of Canagliflozin.Testosterone enanthate may increase the hypoglycemic activities of Metformin.Testosterone enanthate may increase the hypoglycemic activities of Canagliflozin.Testosterone propionate may increase the hypoglycemic activities of Metformin.Testosterone propionate may increase the hypoglycemic activities of Canagliflozin.Testosterone undecanoate may increase the hypoglycemic activities of Metformin.Testosterone undecanoate may increase the hypoglycemic activities of Canagliflozin.Metformin may decrease the excretion rate of Tetracycline which could result in a higher serum level.Tetracycline may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Metformin may decrease the excretion rate of Tetradecyl hydrogen sulfate (ester) which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Tetradecyl hydrogen sulfate (ester) which could result in a higher serum level.The risk or severity of adverse effects can be increased when Thalidomide is combined with Canagliflozin.The risk or severity of adverse effects can be increased when Thioridazine is combined with Canagliflozin.Ticlopidine may decrease the excretion rate of Metformin which could result in a higher serum level.Ticlopidine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Metformin may decrease the excretion rate of Tinidazole which could result in a higher serum level.Tinidazole may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The risk or severity of hyperkalemia can be increased when Tinzaparin is combined with Canagliflozin.Metformin may decrease the excretion rate of Tiopronin which could result in a higher serum level.Tiopronin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Metformin may decrease the excretion rate of Tiotropium which could result in a higher serum level.Tiotropium may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Tipranavir.Metformin may decrease the excretion rate of Tirofiban which could result in a higher serum level.Tirofiban may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The risk or severity of adverse effects can be increased when Tizanidine is combined with Canagliflozin.Metformin may decrease the excretion rate of Tocopherol which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Tocopherol which could result in a higher serum level.Canagliflozin may increase the hypotensive activities of Tocopherylquinone.Tolcapone may decrease the excretion rate of Metformin which could result in a higher serum level.The risk or severity of adverse effects can be increased when Tolcapone is combined with Canagliflozin.Tolmetin may decrease the excretion rate of Metformin which could result in a higher serum level.The risk or severity of hyperkalemia can be increased when Tolmetin is combined with Canagliflozin.Metformin may decrease the excretion rate of Tolterodine which could result in a higher serum level.Tolterodine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Tolvaptan may increase the excretion rate of Metformin which could result in a lower serum level and potentially a reduction in efficacy.Topiramate may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Torasemide.Tramadol may decrease the excretion rate of Metformin which could result in a higher serum level.Tramadol may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Metformin may decrease the excretion rate of Trametinib which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Trametinib which could result in a higher serum level.The risk or severity of lactic acidosis can be increased when Trandolapril is combined with Metformin.Tranylcypromine may increase the hypoglycemic activities of Metformin.Canagliflozin may increase the hypotensive activities of Treprostinil.The therapeutic efficacy of Metformin can be decreased when used in combination with Triamcinolone.Triamterene may decrease the excretion rate of Metformin which could result in a higher serum level.The risk or severity of adverse effects can be increased when Triamterene is combined with Canagliflozin.Metformin may decrease the excretion rate of Triazolam which could result in a higher serum level.Triazolam may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Metformin may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.Triethylenetetramine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Metformin may decrease the excretion rate of Trifluridine which could result in a higher serum level.Trifluridine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Canagliflozin.Metformin may decrease the excretion rate of Trimetrexate which could result in a higher serum level.Trimetrexate may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Triptorelin.The serum concentration of Trospium can be decreased when it is combined with Metformin.Metformin may decrease the excretion rate of Vaborbactam which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Vaborbactam which could result in a higher serum level.The serum concentration of Canagliflozin can be increased when it is combined with Vadadustat.Valaciclovir may decrease the excretion rate of Metformin which could result in a higher serum level.Valaciclovir may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Metformin may decrease the excretion rate of Valbenazine which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Valbenazine which could result in a higher serum level.The therapeutic efficacy of Metformin can be increased when used in combination with Valdecoxib.The risk or severity of hyperkalemia can be increased when Valdecoxib is combined with Canagliflozin.Metformin may decrease the excretion rate of Valganciclovir which could result in a higher serum level.Valganciclovir may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Varenicline may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The therapeutic efficacy of Metformin can be increased when used in combination with Vemurafenib.The risk or severity of adverse effects can be increased when Canagliflozin is combined with Vericiguat.Metformin may decrease the excretion rate of Vilanterol which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Vilanterol which could result in a higher serum level.Metformin may decrease the excretion rate of Viloxazine which could result in a higher serum level.The metabolism of Canagliflozin can be decreased when combined with Viloxazine.The therapeutic efficacy of Metformin can be decreased when used in combination with Vorinostat.Metformin may decrease the excretion rate of Vortioxetine which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Vortioxetine which could result in a higher serum level.Metformin may decrease the excretion rate of Zaleplon which could result in a higher serum level.Zaleplon may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Metformin may decrease the excretion rate of Zanamivir which could result in a higher serum level.Zanamivir may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Ziprasidone.
A therapy excluded from this list of known interactions does not necessarily mean that no interactions exist between that therapy and and Invokamet ®.
Abametapir
Abemaciclib
Abemaciclib
Amiodarone
Atazanavir
Axitinib
Bendamustine
Binimetinib
Bortezomib
Cabergoline
Carfilzomib
Ceritinib
Clarithromycin
Cobimetinib
Conivaptan
Crizotinib
Curcumin
Cyclosporine
Dacomitinib
Dactinomycin
Danazol
Darunavir
Dasatinib
Elvitegravir
Ergotamine
Etoposide
Gemcitabine
Imipramine
Indinavir
Iomeprol
Itraconazole
Ketoconazole
Levoketoconazole
Lonafarnib
Lopinavir
Methimazole
Midostaurin
Mitotane
Nefazodone
Nelfinavir
Nilotinib
Nortriptyline
Osimertinib
Panobinostat
Pomalidomide
Posaconazole
Procainamide
Quinidine
Regorafenib
Ribociclib
Rifapentine
Rimegepant
Romidepsin
Saquinavir
Silodosin
Sirolimus
Spironolactone
Telithromycin
Temsirolimus
Tepotinib
Tipranavir
Tolvaptan
Topotecan
Trastuzumab emtansine
Trimipramine
Venetoclax
Vinblastine
Voriconazole
Abrocitinib
Acarbose
Acebutolol
Acebutolol
Acetazolamide
Acetylsalicylic acid
Acetylsalicylic acid
Acyclovir
Adagrasib
Afatinib
Alclometasone
Alclometasone
Alogliptin
Amantadine
Ambrisentan
Amcinonide
Amcinonide
Amikacin
Amikacin
Amiloride
Aminosalicylic acid
Aminosalicylic acid
Amiodarone
Amitriptyline
Amitriptyline
Amlodipine
Amlodipine
Amobarbital
Amoxapine
Amoxapine
Apalutamide
Apalutamide
Apixaban
Aprepitant
Aripiprazole
Arsenic trioxide
Articaine
Asciminib
Asenapine
Asunaprevir
Atenolol
Atenolol
Avanafil
Azilsartan medoxomil
Baclofen
Baclofen
Balsalazide
Balsalazide
Baricitinib
Beclomethasone dipropionate
Belinostat
Belumosudil
Benazepril
Benazepril
Bendroflumethiazide
Berotralstat
Betamethasone
Betaxolol
Betaxolol
Betrixaban
Bexagliflozin
Bexagliflozin
Bismuth subsalicylate
Bismuth subsalicylate
Bisoprolol
Bisoprolol
Bosutinib
Brentuximab vedotin
Brexpiprazole
Brigatinib
Bromocriptine
Bromocriptine
Budesonide
Budesonide
Bumetanide
Bupropion
Butalbital
Candesartan cilexetil
Cannabidiol
Capivasertib
Capmatinib
Capmatinib
Capreomycin
Capreomycin
Captopril
Carbamazepine
Carbamazepine
Carvedilol
Carvedilol
Cenobamate
Cephalexin
Chlorothiazide
Chlorpheniramine
Chlorpromazine
Chlorthalidone
Choline
Choline salicylate
Choline salicylate
Ciclesonide
Ciprofloxacin
Ciprofloxacin
Cisplatin
Citalopram
Citalopram
Clevidipine
Clevidipine
Clobazam
Clobetasol propionate
Clocortolone
Clocortolone
Clomifene
Clomipramine
Clomipramine
Clopidogrel
Clozapine
Cobicistat
Colchicine
Colistin
Colistin
Conjugated estrogens
Conjugated estrogens
Corticotropin
Cortisone acetate
Crizotinib
Dabigatran etexilate
Dabrafenib
Danicopan
Dapagliflozin
Daptomycin
Darolutamide
Dasabuvir
Deferasirox
Deflazacort
Delafloxacin
Delafloxacin
Desipramine
Desipramine
Desogestrel
Desonide
Desonide
Desoximetasone
Desoximetasone
Desvenlafaxine
Desvenlafaxine
Dexamethasone
Dexamethasone acetate
Dexamethasone acetate
Dexchlorpheniramine maleate
Diazoxide
Diclofenamide
Dienogest
Diflorasone
Diflorasone
Diflunisal
Diflunisal
Difluprednate
Difluprednate
Digoxin
Digoxin
Diltiazem
Diltiazem
Dinoprostone
Diosmin
Diphenhydramine
Dipotassium phosphate
Disopyramide
Disopyramide
Dofetilide
Dolutegravir
Dolutegravir
Dopamine
Doxepin
Doxepin
Doxorubicin
Dronedarone
Dronedarone
Drospirenone
Dulaglutide
Dulaglutide
Duloxetine
Duvelisib
Edoxaban
Efavirenz
Elacestrant
Elagolix
Elbasvir
Eliglustat
Eltrombopag
Empagliflozin
Enalapril
Enalaprilat
Enasidenib
Enasidenib
Encorafenib
Encorafenib
Enfortumab vedotin
Entrectinib
Enzalutamide
Epcoritamab
Epinephrine
Eprosartan
Erdafitinib
Erdafitinib
Ertugliflozin
Erythromycin
Escitalopram
Escitalopram
Estetrol
Estetrol
Estradiol
Estradiol acetate
Estradiol cypionate
Estradiol valerate
Estrone sulfate
Etacrynic acid
Ethanol
Ethinylestradiol
Ethosuximide
Ethosuximide
Ethynodiol diacetate
Etonogestrel
Everolimus
Exenatide
Exenatide
Famotidine
Fedratinib
Fedratinib
Felodipine
Felodipine
Fexinidazole
Fexofenadine
Flibanserin
Fluconazole
Fluconazole
Fludrocortisone
Flunisolide
Flunisolide
Fluocinolone acetonide
Fluocinolone acetonide
Fluocinonide
Fluocinonide
Fluorometholone
Fluoxetine
Fluoxetine
Flurandrenolide
Flurandrenolide
Flurazepam
Fluticasone furoate
Fluticasone propionate
Fluticasone propionate
Fluvoxamine
Fluvoxamine
Fosamprenavir
Fosinopril
Fosnetupitant
Fosphenytoin
Fostemsavir
Furosemide
Fusidic acid
Futibatinib
Ganciclovir
Gatifloxacin
Gatifloxacin
Gemifloxacin
Gemifloxacin
Gentamicin
Gentamicin
Gilteritinib
Glasdegib
Glasdegib
Glecaprevir
Glimepiride
Glipizide
Glofitamab
Glyburide
Goserelin
Grazoprevir
Guanidine
Halcinonide
Halcinonide
Haloperidol
Histamine
Histrelin
Hydrochlorothiazide
Hydrocortisone
Hydrocortisone acetate
Hydrocortisone acetate
Hydrocortisone butyrate
Hydrocortisone butyrate
Hydrocortisone probutate
Hydrocortisone probutate
Hydrocortisone succinate
Hydrocortisone succinate
Hydrocortisone valerate
Hydrocortisone valerate
Hydroflumethiazide
Hydroflumethiazide
Hydroxychloroquine
Hydroxychloroquine
Hydroxyprogesterone caproate
Idelalisib
Iloperidone
Imatinib
Imipramine
Indapamide
Indomethacin
Indomethacin
Insulin aspart
Insulin aspart
Insulin degludec
Insulin degludec
Insulin detemir
Insulin detemir
Insulin glargine
Insulin glargine
Insulin glulisine
Insulin glulisine
Insulin human
Insulin human
Insulin lispro
Insulin lispro
Iodixanol
Iohexol
Iopamidol
Iopromide
Ioversol
Irbesartan
Isavuconazonium
Isavuconazonium
Isocarboxazid
Isoniazid
Isradipine
Isradipine
Istradefylline
Istradefylline
Ivacaftor
Ivosidenib
Ixabepilone
Labetalol
Labetalol
Lanreotide
Lapatinib
Lasmiditan
Ledipasvir
Lefamulin
Lemborexant
Lenacapavir
Lenvatinib
Lenvatinib
Leuprolide
Levamlodipine
Levamlodipine
Levofloxacin
Levofloxacin
Levoketoconazole
Levomilnacipran
Levomilnacipran
Levonorgestrel
Levothyroxine
Linagliptin
Linezolid
Liothyronine
Liothyronine
Lipoic acid
Liraglutide
Liraglutide
Lisinopril
Lixisenatide
Lixisenatide
Lomefloxacin
Lomefloxacin
Lomitapide
Lonapegsomatropin
Lonapegsomatropin
Loncastuximab tesirine
Losartan
Loxapine
Lumacaftor
Lurasidone
Lusutrombopag
Magnesium sulfate
Magnesium sulfate
Mannitol
Maribavir
Mavacamten
Mavorixafor
Mecasermin
Mecasermin
Medroxyprogesterone acetate
Medrysone
Medrysone
Mefenamic acid
Mefloquine
Megestrol acetate
Mesalazine
Mesalazine
Methazolamide
Methohexital
Methsuximide
Methsuximide
Methyl salicylate
Methyl salicylate
Methylene blue
Methylene blue
Methylprednisolone
Methylprednisolone hemisuccinate
Methylprednisolone hemisuccinate
Metolazone
Metoprolol
Metoprolol
Miconazole
Midazolam
Mifepristone
Mifepristone
Miglitol
Milnacipran
Milnacipran
Mirabegron
Mitapivat
Moexipril
Mometasone furoate
Monopotassium phosphate
Morphine
Moxifloxacin
Moxifloxacin
Nadolol
Nadolol
Naloxegol
Nateglinide
Nebivolol
Nebivolol
Nefazodone
Neomycin
Neomycin
Neratinib
Netupitant
Niacin
Nicardipine
Nicardipine
Nicotine
Nifedipine
Nifedipine
Nimodipine
Nimodipine
Nintedanib
Nirogacestat
Nisoldipine
Nisoldipine
Norepinephrine
Norethisterone
Norgestimate
Nortriptyline
Octreotide
Octreotide
Ofloxacin
Ofloxacin
Olanzapine
Olmesartan
Olsalazine
Olsalazine
Omadacycline
Ombitasvir
Pacritinib
Palbociclib
Paliperidone
Paritaprevir
Paroxetine
Paroxetine
Pasireotide
Patiromer
Pazopanib
Pegvisomant
Pegvisomant
Pemetrexed
Pemetrexed
Pentamidine
Pentobarbital
Pentostatin
Pentostatin
Perindopril
Pexidartinib
Phenelzine
Phenobarbital
Phenoxybenzamine
Phentermine
Phentermine
Phenytoin
Pibrentasvir
Pinaverium
Pinaverium
Pindolol
Pindolol
Pioglitazone
Piperine
Pirtobrutinib
Pitolisant
Plazomicin
Plazomicin
Polythiazide
Ponatinib
Potassium
Potassium acetate
Potassium bicarbonate
Potassium bitartrate
Potassium carbonate
Potassium cation
Potassium chloride
Potassium citrate
Potassium hydroxide
Potassium Iodide
Potassium nitrate
Potassium sulfate
Potassium triiodide
Pralsetinib
Pralsetinib
Pramlintide
Pramlintide
Pravastatin
Prednicarbate
Prednicarbate
Prednisolone
Prednisolone acetate
Prednisolone acetate
Prednisolone phosphate
Prednisolone phosphate
Prednisone
Pregabalin
Pregabalin
Pretomanid
Primaquine
Primidone
Probenecid
Procainamide
Procaine
Procarbazine
Progesterone
Propafenone
Propafenone
Propranolol
Propranolol
Protriptyline
Protriptyline
Prucalopride
Pseudoephedrine
Pyrimethamine
Quetiapine
Quinapril
Quinidine
Quinine
Quinine
Quizartinib
Ramipril
Ranitidine
Ranolazine
Ranolazine
Rasagiline
Relebactam
Relugolix
Repaglinide
Repotrectinib
Repotrectinib
Reserpine
Revefenacin
Rifampin
Rifaximin
Riociguat
Ripretinib
Risdiplam
Ritlecitinib
Ritonavir
Rivaroxaban
Rolapitant
Rosiglitazone
Safinamide
Salicylic acid
Salicylic acid
Salmeterol
Sapropterin
Sarecycline
Satralizumab
Saxagliptin
Secobarbital
Selegiline
Selexipag
Selumetinib
Semaglutide
Semaglutide
Sertraline
Sertraline
Sildenafil
Simvastatin
Sitagliptin
Sodium ferric gluconate complex
Sodium phosphate, monobasic
Sofosbuvir
Somapacitan
Somapacitan
Somatotropin
Somatotropin
Somatrogon
Somatrogon
Sorafenib
Sotagliflozin
Sotagliflozin
Sotalol
Sotalol
Sotorasib
Sparsentan
Stiripentol
Streptomycin
Streptomycin
Sulfadiazine
Sulfadiazine
Sulfamethoxazole
Sulfamethoxazole
Sulfasalazine
Sulfasalazine
Sunitinib
Sunitinib
Suvorexant
Tacrolimus
Tafenoquine
Tamoxifen
Tazemetostat
Tazemetostat
Technetium Tc-99m sestamibi
Tegaserod
Telmisartan
Telotristat ethyl
Tenofovir alafenamide
Tenofovir alafenamide
Tenofovir disoproxil
Teprotumumab
Tezacaftor
Thiamine
Thyroid, porcine
Thyroid, porcine
Thyrotropin alfa
Thyrotropin alfa
Ticagrelor
Timolol
Timolol
Tirzepatide
Tirzepatide
Tivozanib
Tixocortol
Tixocortol
Tobramycin
Tobramycin
Tolazamide
Tolazamide
Topiramate
Topotecan
Torasemide
Toremifene
Trandolapril
Tranylcypromine
Triamcinolone
Trilaciclib
Trilaciclib
Trimethoprim
Trimipramine
Triptorelin
Trolamine salicylate
Trolamine salicylate
Trovafloxacin
Trovafloxacin
Tucatinib
Tucatinib
Ubidecarenone
Ubidecarenone
Ubrogepant
Ulobetasol
Ulobetasol
Umeclidinium
Valsartan
Vamorolone
Vamorolone
Vancomycin
Vancomycin
Vandetanib
Vandetanib
Vardenafil
Varenicline
Velpatasvir
Vemurafenib
Venlafaxine
Venlafaxine
Verapamil
Verapamil
Vimseltinib
Vimseltinib
Vincristine
Voclosporin
Vorapaxar
Vorinostat
Voxilaprevir
Warfarin
Warfarin
Xylometazoline
Xylometazoline
Ziconotide
Ziconotide
Ziprasidone
Zonisamide
Zonisamide
Abacavir
Abacavir
Abaloparatide
Acarbose
Aceclofenac
Aceclofenac
Acetaminophen
Acetazolamide
Acetyl sulfisoxazole
Acetyl sulfisoxazole
Aclidinium
Aclidinium
Acrivastine
Acrivastine
Acyclovir
Adefovir dipivoxil
Adefovir dipivoxil
Albuterol
Albuterol
Albutrepenonacog alfa
Albutrepenonacog alfa
Aldesleukin
Aldesleukin
Aliskiren
Allopurinol
Allopurinol
Almasilate
Almasilate
Almotriptan
Almotriptan
Alprazolam
Alprazolam
Amantadine
Amifostine
Amiloride
Ammonium chloride
Ammonium chloride
Amoxicillin
Amoxicillin
Amphetamine
Amphetamine
Amphotericin B
Amphotericin B
Ampicillin
Ampicillin
Amyl Nitrite
Antipyrine
Antipyrine
Antithrombin III human
Antithrombin III human
Apomorphine
Apremilast
Apremilast
Aprocitentan
Arformoterol
Arformoterol
Arimoclomol
Aripiprazole
Aripiprazole lauroxil
Arsenic trioxide
Articaine
Asenapine
Atazanavir
Atomoxetine
Atomoxetine
Atorvastatin
Auranofin
Auranofin
Azacitidine
Azacitidine
Azathioprine
Azathioprine
Azelaic acid
Azelaic acid
Aztreonam
Aztreonam
Bacitracin
Bacitracin
Baricitinib
Beclomethasone dipropionate
Bendroflumethiazide
Benzatropine
Benzatropine
Benznidazole
Benznidazole
Bepotastine
Bepotastine
Betamethasone
Bicisate
Bicisate
Bictegravir
Bismuth subgallate
Bismuth subgallate
Bleomycin
Bleomycin
Bosentan
Bosentan
Bretylium
Brexpiprazole
Brivaracetam
Brivaracetam
Bromotheophylline
Bromotheophylline
Bumetanide
Bupivacaine
Bupropion
Buspirone
Buspirone
Capecitabine
Capecitabine
Captopril
Carbidopa
Carbidopa
Carboplatin
Carboplatin
Carmustine
Carmustine
Cefaclor
Cefaclor
Cefadroxil
Cefadroxil
Cefazolin
Cefazolin
Cefdinir
Cefdinir
Cefditoren
Cefditoren
Cefepime
Cefepime
Cefotaxime
Cefotaxime
Cefotetan
Cefotetan
Cefoxitin
Cefoxitin
Cefpodoxime
Cefpodoxime
Cefprozil
Cefprozil
Ceftaroline fosamil
Ceftaroline fosamil
Ceftazidime
Ceftazidime
Ceftibuten
Ceftibuten
Ceftizoxime
Ceftizoxime
Ceftolozane
Ceftolozane
Ceftriaxone
Ceftriaxone
Cefuroxime
Cefuroxime
Celecoxib
Celecoxib
Cephalexin
Ceritinib
Certolizumab pegol
Certolizumab pegol
Cetirizine
Cetirizine
Cevimeline
Cevimeline
Chloroquine
Chloroquine
Chlorothiazide
Chlorpromazine
Chlorthalidone
Chlorzoxazone
Chlorzoxazone
Chondroitin sulfate
Chondroitin sulfate
Chromic chloride
Chromic chloride
Chromium
Chromium
Chromium nicotinate
Chromium nicotinate
Ciclesonide
Cidofovir
Cidofovir
Cilostazol
Cilostazol
Cimetidine
Cimetidine
Clobazam
Clobetasol propionate
Clofarabine
Clofarabine
Clonazepam
Clonazepam
Clonidine
Clorazepic acid
Clorazepic acid
Clove oil
Clove oil
Clozapine
Colchicine
Colistimethate
Colistimethate
Conivaptan
Corticotropin
Cortisone acetate
Cyanocobalamin
Cyanocobalamin
Cyclosporine
Dabigatran etexilate
Dabrafenib
Dacarbazine
Dacarbazine
Dalfampridine
Dalfampridine
Dalteparin
Danazol
Dantrolene
Daptomycin
Darunavir
Dasiglucagon
Deferiprone
Deferiprone
Deflazacort
Desflurane
Desmopressin
Desmopressin
Desogestrel
Deutetrabenazine
Deutetrabenazine
Dexamethasone
Dexmedetomidine
Dexmedetomidine
Dexpanthenol
Dexpanthenol
Dexrazoxane
Dexrazoxane
Dextran
Dextran
Diatrizoate
Diatrizoate
Diazepam
Diazepam
Diazoxide
Diclofenac
Diclofenac
Diclofenamide
Dicyclomine
Dicyclomine
Didanosine
Didanosine
Dienogest
Dimercaprol
Dimercaprol
Dimethyl sulfoxide
Dimethyl sulfoxide
Dinutuximab
Dipyridamole
DL-Methylephedrine
DL-Methylephedrine
Dobutamine
Dobutamine
Dopamine
Doxazosin
Doxycycline
Doxycycline
Drospirenone
Droxidopa
Droxidopa
Duloxetine
Edoxaban
Edrophonium
Edrophonium
Emtricitabine
Enalapril
Enalaprilat
Enoxaparin
Ensartinib
Enzalutamide
Epinephrine
Eplerenone
Eplerenone
Epoprostenol
Epoprostenol
Ertapenem
Ertapenem
Esmolol
Estazolam
Estazolam
Estradiol
Estradiol acetate
Estradiol cypionate
Estradiol valerate
Estrone sulfate
Eszopiclone
Eszopiclone
Etacrynic acid
Ethambutol
Ethambutol
Ethenzamide
Ethenzamide
Ethinylestradiol
Ethynodiol diacetate
Etodolac
Etodolac
Etomidate
Etomidate
Etonogestrel
Eucalyptus oil
Eucalyptus oil
Evening primrose oil
Evening primrose oil
Everolimus
Fenofibrate
Fenofibric acid
Fenofibric acid
Fenoldopam
Fenoldopam
Fenoprofen
Fenoprofen
Fentanyl
Fentanyl
Fesoterodine
Fesoterodine
Finerenone
Finerenone
Fish oil
Flavoxate
Flavoxate
Flecainide
Florbetaben F-18
Florbetaben F-18
Florbetapir F-18
Florbetapir F-18
Floxuridine
Floxuridine
Flucytosine
Flucytosine
Fludeoxyglucose (18F)
Fludeoxyglucose (18F)
Fludrocortisone
Flumazenil
Flumazenil
Fluorometholone
Fluoxymesterone
Fluoxymesterone
Flurazepam
Flurbiprofen
Flurbiprofen
Flutamide
Flutamide
Fluticasone furoate
Fluvastatin
Folic acid
Folic acid
Fomepizole
Fomepizole
Fondaparinux
Fondaparinux
Fosamprenavir
Foscarnet
Foscarnet
Fosfomycin
Fosfomycin
Fosinopril
Fostamatinib
Furosemide
Gabapentin enacarbil
Gabapentin enacarbil
Gadobenic acid
Gadobenic acid
Gadodiamide
Gadodiamide
Gadofosveset trisodium
Gadofosveset trisodium
Gadoteric acid
Gadoteric acid
Gadoteridol
Gadoteridol
Ganciclovir
Gemcitabine
Gemfibrozil
Gemfibrozil
Gilteritinib
Givosiran
Givosiran
Glycerol phenylbutyrate
Glycerol phenylbutyrate
Glycopyrronium
Golodirsen
Golodirsen
Goserelin
Guanfacine
Guanfacine
Haloperidol
Heparin
Histrelin
Hydralazine
Hydralazine
Hydrochlorothiazide
Hydrocortisone
Hydromorphone
Hydromorphone
Hydroxocobalamin
Hydroxocobalamin
Hydroxyethyl Starch
Hydroxyethyl Starch
Hydroxyprogesterone caproate
Ibuprofen
Ibuprofen
Ibutilide
Ibutilide
Icatibant
Icatibant
Icosapent
Icosapent
Idarucizumab
Idarucizumab
Ifosfamide
Ifosfamide
Iloperidone
Iloprost
Indapamide
Indigotindisulfonic acid
Indigotindisulfonic acid
Indinavir
Inositol
Inositol
Inotersen
Inotersen
Iobenguane sulfate I-123
Iobenguane sulfate I-123
Iodixanol
Ioflupane I-123
Ioflupane I-123
Iopromide
Iothalamic acid
Iothalamic acid
Ioversol
Ipecac
Ipecac
Ipilimumab
Ipilimumab
Isocarboxazid
Isoflurane
Isoniazid
Isosorbide
Isosorbide
Isosorbide dinitrate
Isosorbide mononitrate
Isosorbide mononitrate
Isosulfan blue
Isosulfan blue
Isotretinoin
Isotretinoin
Isoxsuprine
Ixazomib
Ixazomib
Ketamine
Ketamine
Ketoprofen
Ketoprofen
Ketorolac
Ketorolac
Ketotifen
Ketotifen
L-Acetylleucine
Lamivudine
Lamivudine
Lamotrigine
Lamotrigine
Landiolol
Lanreotide
Ledipasvir
Lenalidomide
Lenalidomide
Leuprolide
Levocarnitine
Levocarnitine
Levocetirizine
Levocetirizine
Levodopa
Levomenthol
Levonorgestrel
Levosalbutamol
Levosalbutamol
Levothyroxine
Linezolid
Lisinopril
Lithium carbonate
Lithium carbonate
Lithium citrate
Lithium citrate
Lofexidine
Lofexidine
Loperamide
Lopinavir
Lorazepam
Lorazepam
Lovastatin
Lubiprostone
Lubiprostone
Lurasidone
Macitentan
Macitentan
Magnesium carbonate
Magnesium carbonate
Magnesium chloride
Magnesium chloride
Magnesium hydroxide
Magnesium hydroxide
Magnesium salicylate
Magnesium salicylate
Magnesium trisilicate
Magnesium trisilicate
Mannitol
Maprotiline
Maprotiline
Mecamylamine
Mecamylamine
Meclofenamic acid
Meclofenamic acid
Medroxyprogesterone acetate
Mefenamic acid
Megestrol acetate
Meloxicam
Meloxicam
Memantine
Memantine
Meperidine
Meperidine
Mepivacaine
Mepivacaine
Meropenem
Meropenem
Metamfetamine
Metamfetamine
Metaxalone
Metaxalone
Methadone
Methadone
Methazolamide
Methimazole
Methotrexate
Methotrexate
Methoxsalen
Methoxsalen
Methyldopa
Methyldopa
Methylnaltrexone
Methylnaltrexone
Methylprednisolone
Methyltestosterone
Methyltestosterone
Metoclopramide
Metoclopramide
Metolazone
Metreleptin
Metyrapone
Metyrapone
Metyrosine
Midazolam
Migalastat
Migalastat
Milrinone
Milrinone
Minoxidil
Mirabegron
Mitapivat
Moexipril
Mometasone furoate
Mycophenolate mofetil
Mycophenolate mofetil
Mycophenolic acid
Mycophenolic acid
N-acetyltyrosine
N-acetyltyrosine
Nabilone
Nabumetone
Nabumetone
Naldemedine
Naldemedine
Nalmefene
Nalmefene
Naloxone
Naloxone
Nandrolone decanoate
Nandrolone decanoate
Naproxen
Naproxen
Nedocromil
Nedocromil
Nelfinavir
Niacin
Nilotinib
Nilutamide
Nilutamide
Nitric Oxide
Nitric Oxide
Nitrofurantoin
Nitrofurantoin
Nitroglycerin
Nitroprusside
Nitroprusside
Nitrous acid
Norethisterone
Norgestimate
Obinutuzumab
Octinoxate
Octinoxate
Olanzapine
Omaveloxolone
Opicapone
Opium
Opium
Oseltamivir
Oseltamivir
Oxacillin
Oxacillin
Oxandrolone
Oxandrolone
Oxaprozin
Oxaprozin
Oxazepam
Oxazepam
Oxybenzone
Oxybenzone
Oxymetholone
Oxymetholone
Oxyquinoline
Oxyquinoline
Paclitaxel
Paliperidone
Palonosetron
Palonosetron
Pamidronic acid
Pamidronic acid
Pantoprazole
Pantoprazole
Papaverine
Parecoxib
Parecoxib
Paromomycin
Paromomycin
Pasireotide
Pentamidine
Pentetic acid
Pentetic acid
Pentobarbital
Pentoxifylline
Pentoxifylline
Perindopril
Permethrin
Permethrin
Phenazopyridine
Phenazopyridine
Phenelzine
Phenoxybenzamine
Phentolamine
Phenytoin
Phosphoric acid
Phosphoric acid
Phylloquinone
Phylloquinone
Picosulfuric acid
Picosulfuric acid
Piperacillin
Piperacillin
Piroxicam
Piroxicam
Pitavastatin
Pitolisant
Plerixafor
Plerixafor
Polythiazide
Pomalidomide
Potassium
Potassium acetate
Potassium bicarbonate
Potassium cation
Potassium chloride
Potassium citrate
Potassium nitrate
Potassium sulfate
Pralatrexate
Pralatrexate
Pralidoxime
Pralidoxime
Pramipexole
Pramipexole
Prasugrel
Prasugrel
Pravastatin
Prazosin
Prednisolone
Prednisone
Probenecid
Procaine
Procaine benzylpenicillin
Procaine benzylpenicillin
Procarbazine
Progesterone
Promethazine
Promethazine
Propantheline
Propantheline
Propofol
Propyphenazone
Propyphenazone
Prucalopride
Pseudoephedrine
Pyrantel
Pyrantel
Pyrazinamide
Pyrazinamide
Pyridoxine
Pyridoxine
Quetiapine
Quinapril
Rabeprazole
Rabeprazole
Ramelteon
Ramelteon
Ramipril
Ranitidine
Rasagiline
Remdesivir
Remifentanil
Reserpine
Resorcinol
Resorcinol
Ribavirin
Ribavirin
Ripretinib
Risperidone
Risperidone
Ritonavir
Rivaroxaban
Rizatriptan
Rizatriptan
Roflumilast
Roflumilast
Ropinirole
Ropivacaine
Ropivacaine
Rosuvastatin
Rotigotine
Ruxolitinib
Ruxolitinib
Sacubitril
Sacubitril
Safinamide
Salicylamide
Salicylamide
Salmon calcitonin
Salmon calcitonin
Salsalate
Salsalate
Saquinavir
Secobarbital
Selegiline
Selenious acid
Selenious acid
Selenium
Selenium
Selpercatinib
Sevoflurane
Simvastatin
Sirolimus
Sodium acetate
Sodium acetate
Sodium fluoride
Sodium fluoride
Sodium sulfate
Sodium sulfate
Sofosbuvir
Solriamfetol
Solriamfetol
Sorafenib
Sorbitol
Sorbitol
Sotatercept
Spironolactone
Stiripentol
Succinylcholine
Sucralfate
Sucralfate
Sufentanil
Sulbactam
Sulbactam
Sulfamethizole
Sulfamethizole
Sulindac
Sulindac
Sumatriptan
Sumatriptan
Synthetic Conjugated Estrogens, A
Synthetic Conjugated Estrogens, A
Synthetic Conjugated Estrogens, B
Synthetic Conjugated Estrogens, B
Tacrolimus
Tadalafil
Tadalafil
Talazoparib
Tamsulosin
Tamsulosin
Tasimelteon
Tasimelteon
Technetium Tc-99m exametazime
Technetium Tc-99m exametazime
Technetium Tc-99m pyrophosphate
Technetium Tc-99m pyrophosphate
Teduglutide
Teduglutide
Telavancin
Telavancin
Temazepam
Temazepam
Temozolomide
Temozolomide
Temsirolimus
Tenofovir disoproxil
Teprotumumab
Terazosin
Terbutaline
Terbutaline
Testosterone
Testosterone
Testosterone cypionate
Testosterone cypionate
Testosterone enanthate
Testosterone enanthate
Testosterone propionate
Testosterone propionate
Testosterone undecanoate
Testosterone undecanoate
Tetracycline
Tetracycline
Tetradecyl hydrogen sulfate (ester)
Tetradecyl hydrogen sulfate (ester)
Thalidomide
Thioridazine
Ticlopidine
Ticlopidine
Tinidazole
Tinidazole
Tinzaparin
Tiopronin
Tiopronin
Tiotropium
Tiotropium
Tipranavir
Tirofiban
Tirofiban
Tizanidine
Tocopherol
Tocopherol
Tocopherylquinone
Tolcapone
Tolcapone
Tolmetin
Tolmetin
Tolterodine
Tolterodine
Tolvaptan
Topiramate
Torasemide
Tramadol
Tramadol
Trametinib
Trametinib
Trandolapril
Tranylcypromine
Treprostinil
Triamcinolone
Triamterene
Triamterene
Triazolam
Triazolam
Triethylenetetramine
Triethylenetetramine
Trifluridine
Trifluridine
Trimethoprim
Trimetrexate
Trimetrexate
Triptorelin
Trospium
Vaborbactam
Vaborbactam
Vadadustat
Valaciclovir
Valaciclovir
Valbenazine
Valbenazine
Valdecoxib
Valdecoxib
Valganciclovir
Valganciclovir
Varenicline
Vemurafenib
Vericiguat
Vilanterol
Vilanterol
Viloxazine
Viloxazine
Vorinostat
Vortioxetine
Vortioxetine
Zaleplon
Zaleplon
Zanamivir
Zanamivir
Ziprasidone